



UNIVERSITÀ DI PARMA

ARCHIVIO DELLA RICERCA

University of Parma Research Repository

Joint position statement on "Nutraceuticals for the treatment of hypercholesterolemia" of the Italian Society of Diabetology (SID) and of the Italian Society for the Study of Arteriosclerosis (SISA)

This is the peer reviewed version of the following article:

Original

Joint position statement on "Nutraceuticals for the treatment of hypercholesterolemia" of the Italian Society of Diabetology (SID) and of the Italian Society for the Study of Arteriosclerosis (SISA) / Pirro, M; Vetrani, C; Bianchi, C; Mannarino, Mr; Bernini, Franco; Rivellese, Aa. - In: NMCD. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES. - ISSN 0939-4753. - 27:1(2017), pp. 2-17. [10.1016/j.numecd.2016.11.122]

Availability:

This version is available at: 11381/2826355 since: 2021-10-12T09:50:13Z

Publisher:

Elsevier B.V.

Published

DOI:10.1016/j.numecd.2016.11.122

Terms of use:

Anyone can freely access the full text of works made available as "Open Access". Works made available

Publisher copyright

note finali coverpage

(Article begins on next page)

Manuscript Number: NMCD-D-16-00342R2

Title: Joint Position Statement on "Nutraceuticals for the treatment of hypercholesterolemia" of the Italian Society of Diabetology (SID) and of the Italian Society for the Study of Arteriosclerosis (SISA)

Article Type: Review Article (max. 3000 words)

Keywords: berberine; cardiovascular risk; cholesterol; fiber; nutraceuticals; phytosterols; policosanol; red yeast rice; soy.

Corresponding Author: Professor Angela A Rivellese, Prof

Corresponding Author's Institution: Federico II University Medical School

First Author: Matteo Pirro

Order of Authors: Matteo Pirro; Claudia Vetrani, RD; Cristina Bianchi; Massimo R Mannarino; Franco Bernini; Angela Albarosa A Rivellese

Abstract: Hypercholesterolemia is a major risk factor for cardiovascular morbidity and mortality. There is a large body of evidence showing that low-density lipoprotein (LDL) cholesterol-lowering is associated with a significant cardiovascular risk reduction, both in primary and secondary prevention.

Treatment strategies to achieve optimal LDL cholesterol levels include both interventions on lifestyle and pharmacological measures. The initial therapeutic approach to patients with hypercholesterolemia includes a low dietary intake of cholesterol, saturated and "trans" fats and an increase in dietary fiber, associated with physical activity. However, patients compliance to these recommendations is often inadequate, especially in the medium to long term. Some dietary components with potential cholesterol-lowering activity are present in small amounts in food. Therefore, in recent years the use of "nutraceuticals" (i.e., nutrients and/or bioactive compounds with potential beneficial effects on human health) has become widespread. Such substances may be added to foods and beverages, or taken in the form of dietary supplements (liquid preparations, tablets, capsules).

A growing number of nutraceuticals with slight to moderate cholesterol-lowering activity have been proposed. However, scientific research regarding the cholesterol-lowering effect of some nutraceuticals has produced conflicting results; in addition, methodological limitations flawed the quality of several trials.

In the present document, the cholesterol-lowering activity of some nutraceuticals (i.e. fiber, phytosterols, soy products, policosanol, red yeast rice and berberine) will be discussed along with: 1) the level of evidence on the cholesterol-lowering efficacy emerging from interventional studies in humans; 2) the possible side effects associated with their use; 3) the categories of patients who could benefit from their use.

**Joint Position Statement on “Nutraceuticals for the treatment of hypercholesterolemia”
of the Italian Society of Diabetology (SID) and of the Italian Society for the Study of Arteriosclerosis
(SISA)**

Matteo Pirro^{a,b}, Claudia Vetrani^{c,d}, Cristina Bianchi^{d,e}, Massimo R. Mannarino^{a,b}, Franco Bernini^{b,f}, Angela A. Rivellese^{c,d*}

^a Unit of Internal Medicine, Department of Medicine, University of Perugia, Perugia, Italy.

^b Italian Society for the Study of Arteriosclerosis (SISA).

^c Department of Clinical Medicine and Surgery, “Federico II” University, Naples, Italy.

^d Italian Society of Diabetology (SID).

^e Unit of Diabetology and Metabolic Diseases, Department of Medical Area “*Azienda Ospedaliero-Universitaria Pisana*”, Pisa, Italy.

^f Department of Pharmacy, University of Parma, Parma, Italy.

*corresponding author: Angela Albarosa Rivellese, Department of Clinical Medicine and Surgery, “Federico II” University, 5, S. Pansini 80131, Naples, Italy. Tel. +39 081 7462154, fax +39 081 7462321, e-mail: rivelles@unina.it

2 Summary

3 Hypercholesterolemia is a major risk factor for cardiovascular morbidity and mortality. There is a large body
4 of evidence showing that low-density lipoprotein (LDL) cholesterol-lowering is associated with a significant
5 cardiovascular risk reduction, both in primary and secondary prevention.

6 Treatment strategies to achieve optimal LDL cholesterol levels include both interventions on lifestyle and
7 pharmacological measures. The initial therapeutic approach to patients with hypercholesterolemia includes a
8 low dietary intake of cholesterol, saturated and "trans" fats and an increase in dietary fiber, associated with
9 physical activity. However, patients compliance to these recommendations is often inadequate, especially in
10 the medium to long term. Some dietary components with potential cholesterol-lowering activity are present
11 in small amounts in food. Therefore, in recent years the use of "nutraceuticals" (i.e., nutrients and/or
12 bioactive compounds with potential beneficial effects on human health) has become widespread. Such
13 substances may be added to foods and beverages, or taken in the form of dietary supplements (liquid
14 preparations, tablets, capsules).

15 A growing number of nutraceuticals with slight to moderate cholesterol-lowering activity have been
16 proposed. However, scientific research regarding the cholesterol-lowering effect of some nutraceuticals has
17 produced conflicting results; in addition, methodological limitations flawed the quality of several trials.

18 In the present document, the cholesterol-lowering activity of some nutraceuticals (i.e. fiber, phytosterols, soy
19 products, policosanol, red yeast rice and berberine) will be discussed along with: 1) the level of evidence on
20 the cholesterol-lowering efficacy emerging from interventional studies in humans; 2) the possible side
21 effects associated with their use; 3) the categories of patients who could benefit from their use.

22
23 **Key words:** berberine, cardiovascular risk, cholesterol, fiber, nutraceuticals, phytosterols, policosanol, red
24 yeast rice, soy.

26 **Introduction**

27 High plasma cholesterol levels are associated with an increased cardiovascular morbidity and mortality, with
28 hypercholesterolemia being listed among the major cardiovascular risk factors (1).

29 A large number of prospective studies have consistently showed a direct and independent association
30 between serum cholesterol and cardiovascular risk (2,3). This correlation appears to be linear, with no
31 evidence of a threshold level above or below which there is a significant change in the slope of the
32 regression line that describes the relationship between cholesterol and cardiovascular risk (1-3).

33 Low-density lipoprotein (LDL) cholesterol reduction, both in primary and secondary prevention trials, is
34 associated with a significant cardiovascular risk reduction (4). There is also evidence showing that the
35 magnitude of cardiovascular risk reduction associated with LDL cholesterol-lowering largely depends on
36 pre-treatment LDL cholesterol levels, estimated cardiovascular risk and timing of the cholesterol-lowering
37 intervention (5- 7). Clinical trials with statins and, more recently with ezetimibe, have reinforced the
38 hypothesis that LDL cholesterol-lowering produces undeniable benefits in terms of cardiovascular risk
39 prevention. In addition, it is largely accepted that the greatest cardiovascular risk reduction is obtained in
40 patients reaching lower plasma LDL cholesterol levels (8,9).

41 The intensity of cholesterol-lowering should be proportional to the initial absolute plasma cholesterol levels,
42 and to the patients' cardiovascular risk, the latter being estimable with specific algorithms and risk charts
43 (1). Furthermore, the higher the patients' risk, more ambitious should be the therapeutic goal to be achieved
44 for LDL cholesterol (1). Likewise, timeliness of cholesterol-lowering intervention is also crucial. This point
45 arises from some considerations: 1) cardiovascular risk associated with cholesterol is cumulative, depending
46 on time of exposure to circulating cholesterol levels (10); 2) patients with genetic forms of
47 hypocholesterolemia (e.g., loss of function mutations of PCSK9 gene), that are characterized by low LDL
48 cholesterol levels from birth, obtain greater cardiovascular risk reduction than it would be expected from
49 their absolute plasma cholesterol levels (11); 3) early prescription of cholesterol-lowering therapy is

50 associated with better therapeutic compliance (12) and more effective prevention of cardiovascular events
51 particularly in patients at higher risk (7, 13).

52 Treatment strategies to achieve optimal plasma LDL cholesterol levels include both lifestyle and
53 pharmacological interventions. The initial therapeutic approach to hypercholesterolemia should always
54 include non-pharmacological measures (1). Low dietary intake of cholesterol, saturated and “trans” fats and
55 increased intake of dietary fiber, as well as exercise programs suited to the patients physical possibilities, are
56 associated with LDL cholesterol reduction and exert beneficial effects on additional cardiovascular risk
57 factors. Lifestyle changes are necessary as a first therapeutic approach in low risk subjects, but also in
58 addition to drug therapy in patients at higher cardiovascular risk. Despite this evidence, the efficacy of
59 lifestyle interventions is often hampered by some limitations: patients compliance is unsatisfactory and poor
60 adherence and maintenance in the medium- to long-term is common (14). In addition, some dietary
61 components with potential cholesterol-lowering activity are present in small amounts in food. Therefore, the
62 use of nutraceuticals has become widespread in recent years. Nutraceuticals are nutrients and/or bioactive
63 compounds of plant or microbial origin, with possible beneficial effects on human health when
64 supplemented in adequate amounts (often above those present in foods). Nutraceuticals may be added to
65 different foods and beverages (fortified foods, supplements), or taken in the form of dietary supplements
66 (liquid preparations, tablets, capsules).

67 A growing number of nutraceuticals with variable cholesterol-lowering activity have been proposed and
68 scientific research regarding some of them has produced conflicting results; in addition, reliability of a
69 number of trials has been flawed by methodological limitations. Based on this background, the cholesterol-
70 lowering activity of the most popular nutraceuticals (i.e., fiber, phytosterols, soy products, policosanol, red
71 yeast rice and berberine) will be discussed along with: 1) the level of evidence on the cholesterol-lowering
72 efficacy rising from interventional studies in humans; 2) the possible side effects associated with their use;
73 3) the categories of patients who could benefit from nutraceutical supplementation.

76 **Fiber**

77 Dietary fiber consists of the edible part of plants that is not digested in the human small intestine and pass
78 through the large intestine quite intact. It includes non-starch polysaccharides (cellulose, hemicellulose,
79 gums, pectins), oligosaccharides (inulin, fructo-oligosaccharides) and lignin.

80 From a functional point of view, dietary fiber is grouped into 4 classes (15):

- 81 1. insoluble, non-fermentable fiber (bran). It is an insoluble fiber that is poorly fermented in the
82 intestine; it can exert mechanical laxative effects;
- 83 2. soluble, non-viscous, fermentable fiber (inulin, dextrin, oligosaccharides). It is quickly and easily
84 fermented in the intestine. It does not cause increased viscosity and it is rapidly and completely
85 fermented by the intestinal microbiota. It may have a prebiotic effect, but it does not exert laxative
86 effects;
- 87 3. soluble, viscous, fermentable fiber (β -glucan, guar gum, pectin, glucomannan). It is quickly
88 fermented and forms a viscous gel in water, increasing chime viscosity and reducing nutrients'
89 absorption. It is rapidly fermented in the intestine, thus losing its laxative effects;
- 90 4. soluble, viscous, non-fermentable fiber (*psyllium*, methylcellulose). It reduces the absorption of
91 nutrients due to its viscosity and exerts laxative effects.

92 The cholesterol-lowering effect of fiber is mainly due to its viscosity. Water soluble viscous fiber forms a
93 gel that binds bile acids in the small intestine and increases their excretion in feces. Cholesterol is a major
94 component of bile; hence, the increased bile acid fecal excretion leads to an increased liver use of
95 cholesterol for bile production. The higher fiber viscosity, the greater its cholesterol-lowering potential
96 (16,17).

97 It has been suggested that products of fiber fermentation in the gut (e.g., short-chain fatty acids) may exert
98 favorable effects on lipid metabolism (18). Observational studies have shown that regular consumption of
99 dietary fiber is associated with a significant cardiovascular risk reduction (19,20). In particular, for each
100 increase of 10 g/day fiber consumption, especially from whole cereals and fruit, 14% reduction in the risk of

101 coronary events and 27% reduction of death from coronary heart disease has been observed (21). The lipid-
102 lowering activity of fiber has been claimed to explain part of these beneficial effects. Several studies have
103 explored the influence of fiber supplementation on plasma lipid levels. Fiber enriched diet, including higher
104 amount of legumes, fruit and vegetables, reduces both total and LDL cholesterol levels (22-24). Conversely,
105 the effect of whole grains on plasma lipid levels is still limited and controversial.

106 A consumption of approximately 35 g/day of fiber has been recommended for cardiovascular disease
107 prevention. Nevertheless, the intake of fiber is far below the recommended daily dose worldwide (25-27); it
108 happens also among Mediterranean populations, which traditionally consumed a larger amount of fiber
109 (26,27). Therefore, in recent years, increasing interest has been addressed to the study of the cholesterol-
110 lowering effect of different types of fiber added to the usual diet. Evidence from randomized controlled trials
111 (RCTs) and meta-analyses is shown in Table 1. Overall, dietary supplementation with fiber including β -
112 glucan (28,29), *psyllium* (28,30,31), pectin (28), guar gum (28) chitosan (32), glucomannan (33) and
113 hydroxypropylmethylcellulose (34,35) reduced significantly plasma LDL cholesterol concentrations in
114 healthy subjects, in patients with either hypercholesterolemia or with diabetes. Reductions of plasma LDL
115 cholesterol levels have been observed also in trials evaluating the effect of fiber supplementation on top of
116 statin therapy; some of these studies have been conducted for a fairly long period (up to six months).

117 The cholesterol-lowering effect of fiber ranges from 4% (chitosan) to 14% (guar gum), with possible
118 variations in relation to the doses used in the different trials. It should be emphasized that this effect can be
119 greater when the daily fiber intake is higher and that even higher doses are unlikely to cause significant side
120 effects. The effect of fiber on triglycerides and high-density lipoprotein (HDL) cholesterol is less clear
121 (Table 1), although some studies suggest a possible influence of fiber in reducing postprandial
122 triglyceridemia (36,37). Additional RCTs are needed to provide a clear answer on whether dietary fiber is
123 able to influence these lipid parameters. In addition to the lipid-lowering effects, fiber improves other
124 parameters, such as plasma glucose and insulin levels, blood pressure and body weight (18).

125 In general, the quality of intervention studies conducted with added fiber are satisfactory and their results
126 seem to be quite comparable. In fact, on the basis of current knowledge, fiber has been the object of a
127 specific claim by the US Food and Drug Administration (FDA) (β -glucan and *psyllium*) and by the
128 European Food Safety Authority (EFSA) (β -glucan, chitosan, glucomannan, guar gum,
129 hydroxypropylmethylcellulose and pectin) for the maintenance of optimal cholesterol levels (Table 2).

130 In conclusion, a regular intake of fiber, mostly that with higher viscosity, reduces LDL cholesterol
131 concentrations. When an adequate intake of fiber with diet alone is not feasible, the use of fiber-containing
132 supplements can be an effective strategy to safely reduce cholesterol levels and possibly cardiovascular risk.
133 Side effects related to excessive intake of fiber are unusual (38,39), except for symptoms of intestinal
134 discomfort with higher doses (bloating, flatulence, meteorism) (39).

135 Overall, the use of added fiber may be advised when people are unable to increase their intake of dietary
136 fiber with natural foods: 1) in the general population; 2) in patients with mild hypercholesterolemia and low
137 to moderate cardiovascular risk; 3) in patients with mild hypercholesterolemia and/or metabolic syndrome.
138 (Table 3)

139139

140 **Phytosterols**

141 Phytosterols and their esterified derivatives, stanols, are bioactive compounds of plant origin; they are
142 structurally similar to cholesterol and are poorly absorbed in the gut (0.5-2% for sterols and 0.04-0.2% for
143 stanols). They are found in small amounts in fruits, vegetables, nuts, seeds, cereals, legumes and vegetal oils
144 and their average dietary consumption is about 300 mg/day, although it may be higher in vegetarians (600
145 mg/day) (40).

146 The cholesterol-lowering effect of phytosterols is mainly due to their structural homology with cholesterol.
147 Phytosterols reduce intestinal cholesterol absorption by competing with dietary and bile cholesterol. In the
148 enterocytes, they are carried back into the intestinal lumen by the ATP-binding cassette sub-family G
149 member 5 (ABCG5) and ABCG8 transporters and excreted in the faeces (41).

150 Cross-sectional studies have shown an inverse association between natural plant sterols intake and LDL
151 cholesterol levels (42-44). In agreement with these findings, RCTs and meta-analyses show that an increased
152 intake of phytosterols reduces significantly plasma total and LDL cholesterol levels by about 12 mg/dL (~8-
153 10%) in healthy subjects and in patients with hypercholesterolemia (45-51) (Table 4). A similar cholesterol
154 reduction has been observed in a meta-analysis of studies performed in diabetic patients (52) (Table 4). The
155 effect of phytosterols on plasma triglycerides and HDL cholesterol levels is unclear. Clinical trials provide
156 conflicting results and meta-analyses show no significant effect of supplementation of phytosterols on these
157 parameters (47,51-53) (Table 4).

158 The cholesterol-lowering effect of phytosterols appears to be higher in patients with plasma LDL cholesterol
159 levels above 160 mg/dL (45-48). Also, phytosterol-induced cholesterol-lowering is greater in patients with
160 heterozygous than in patients with homozygous hypercholesterolemia (54). No evidence of interaction of
161 phytosterols with most lipid-lowering drugs (statins, ezetimibe, fibrates) has been described. Moreover, an
162 additive cholesterol-lowering effect has been described when phytosterols are taken in combination with
163 statins and ezetimibe (40).

164 The efficacy of phytosterols in reducing plasma cholesterol levels is dose dependent for doses below 3
165 g/day; above this dose a plateau effect is commonly observed without any further significant LDL
166 cholesterol-lowering effect. Moreover, it has been shown that the efficacy of phytosterols and stanols is
167 similar up to a daily consumption of 2 g (55), the latter being the dose of phytosterols recommended by most
168 scientific societies (1,56-58).

169 A sufficient intake of phytosterols is rarely provided by diet, even in vegetarians; therefore, phytosterols are
170 used to enrich foods and drinks (e.g., margarine, yogurt drinks, cream cheese, bakery products) or may be
171 part of specific supplements.

172 Phytosterols have no significant side effects when they are used at the recommended doses. However, an
173 excessive intake of phytosterols may be associated with a reduced intestinal absorption of fat-soluble
174 vitamins; therefore, patients taking high doses of phytosterols should be informed of this possible risk.

175 Sitosterolaemia is a rare autosomal recessive disease characterized by phytosterols' accumulation due to
176 ABCG5 or ABCG8 gene mutations. Homozygosity for this condition is characterized by an abnormally high
177 intestinal absorption of sterols, severe hypercholesterolemia, early atherosclerosis development and
178 increased cardiovascular morbidity and mortality (59). Conversely, heterozygous patients are asymptomatic
179 and can tolerate the intake of sterols with diet, although it has not still defined the threshold above which
180 consumption of phytosterols may be harmful for these individuals. No side effects for regular consumption
181 of 2 g/day of phytosterols have been recorded.

182 Data on the hypocholesterolemic effect of phytosterols derive from good quality intervention studies
183 performed in a quite large number of subjects; overall, the results reported appear to be quite consistent. In
184 this light, FDA and EFSA released a claim related to the use of phytosterols for LDL cholesterol reduction
185 (Table 2). EFSA recommended not to exceed a dose of 3 g/day and suggests that patients receiving lipid-
186 lowering medications should use phytosterols under medical supervision. FDA released a health claim
187 recognizing the reduction of coronary artery disease risk for a dose of phytosterols up to 3.4 g/day. Similarly
188 to most nutraceuticals, the cost of phytosterol supplementation should be considered, because continuous
189 treatment is needed over time to maintain its cholesterol-lowering efficacy (Table 3).

190 In accordance with the major international scientific societies (1,56-58), the regular use of 2 g/day of
191 phytosterols under medical supervision may be advised for reducing LDL cholesterol by 10%:

192 1) in patients with mild hypercholesterolemia and low to moderate cardiovascular risk, when drug therapy
193 is not yet indicated; 2) in patients already on drug therapy who cannot achieve the recommended LDL
194 cholesterol target levels; 3) in patients with documented intolerance to multiple statins (Table 3).

195195

196 Soy

197 Soy (*Glycine max*) is an East Asian native leguminous plant, rich in proteins (36-46%, depending on the
198 variety), lipids (18%), soluble carbohydrates (15%) and fiber (15%). The high content of essential amino
199 acids is a particular feature of soy compared to other legumes. Soy contains also several micronutrients such

200 as lecithin (0.5%), sterols (0.3%), isoflavones (0.1%), tocopherols (0.02%) and low levels of tocotrienols,
201 lignans and sphingolipids (60). Nutritional properties and health benefits of soy have been studied for many
202 years, with epidemiological observations suggesting an inverse relationship between soy consumption and
203 cardiovascular risk. The cholesterol-lowering effect of soy is generally attributed to its isoflavone content.
204 Isoflavones are phytoestrogens which are able to bind the estrogen receptor and to exert estrogen-like
205 activity. They affect lipid metabolism either directly by modulating lipogenesis and lipolysis, or indirectly
206 by regulating appetite and energy balance (61). Soybean processing techniques, varieties of soy and
207 culturing conditions influence the amount of soy isoflavones (62). Whole soybean, that is less consumed in
208 Western countries, has the highest concentration of isoflavones, whose content decreases progressively with
209 the increasing degree of soybean processing (62).

210 The cholesterol-lowering effect of soy (63) may be related also to its content in lecithin, phytosterols and β -
211 glucan, which are able to reduce intestinal cholesterol absorption (60,64). Moreover, soy proteins including
212 β -conglycinin (7S globulin) and glycinin (11S globulin), and peptides obtained by their intestinal hydrolysis
213 may exert cholesterol-lowering effects by promoting LDL-receptor (LDLR) expression (65,66).

214 A meta-analysis of 38 studies performed between 1967 and 1994, concluded that soy proteins are able to
215 reduce LDL cholesterol levels by 12.9% (67). This observation has prompted FDA to release a claim in
216 1999 (Table 2) stating that dietary intake of 25 g/day of soy protein can reduce cardiovascular risk (68).
217 Several meta-analyses (50,69-76) have later demonstrated that soy protein-induced LDL cholesterol
218 reduction ranged from 4% to 6% (Table 5). In 2012, EFSA has rejected a claim on the possible beneficial
219 effects of soy because of lack of evidence of a clear cause-effect relationship (77). However, more recently
220 Health Canada observed that 33% of interventional studies with either isolated or concentrated soy proteins
221 found a significant reduction in plasma LDL cholesterol levels (78). Overall, trials performed in recent years
222 have provided contradictory results on the cholesterol-lowering effects of soy (77-81).

223 The inconsistency of these data might have different explanations. Soy contains several bioactive
224 components exerting a possible influence on plasma LDL cholesterol levels, although it is not clear which of

225 them is primarily responsible for the greatest cholesterol-lowering effect; type, dose and duration of soy
226 supplementation and the different characteristics of the studied populations make results of these trials
227 difficult to be interpreted and compared each other. Finally, it should be kept in mind that a statistically
228 significant but modest reduction in plasma LDL cholesterol levels might not necessarily be associated with a
229 significant clinical benefit, given the absence of data on cardiovascular outcomes. Therefore, since soy is a
230 source of vegetable protein, fiber, unsaturated fats, vitamins, minerals and phytonutrients its dietary intake
231 can be encouraged. In addition, consumption of soy products can be a useful substitute for animal source
232 foods that naturally contain more saturated fat and cholesterol.

233 Evidence on the cholesterol-lowering effect of dietary supplementation with soy products is currently
234 contradictory; thus, such supplementation may be advised but with some level of uncertainty: 1) in the
235 general population; 2) in patients with mild hypercholesterolemia and low to moderate cardiovascular risk
236 (Table 3).

237237

238 **Policosanol**

239 Policosanol (PCS) is a mixture of long chain linear aliphatic alcohols (octacosanol, tetracosanol,
240 hexacosanol, and others) that are present in beeswax, potatoes, rice bran and in sugar cane (82). The
241 mechanism behind PCS-induced cholesterol-lowering has not yet been fully elucidated. It has been suggested
242 that PCS inhibits 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMGCoA) reductase, thus reducing
243 cholesterol synthesis (83,84). PCS has been used as lipid-lowering agent in Cuba since 1991; until 2004,
244 scientific literature on the potential cholesterol-lowering effect of PCS was derived from studies in Cuba
245 (85-99). These studies (100,101) showed that sugar cane-derived PCS reduced LDL cholesterol similarly to
246 statins and more than plant sterols; in addition, PCS raised plasma HDL cholesterol levels without
247 significant side effects (Table 6). PCS-induced cholesterol-lowering seems to be dose dependent in a dose
248 range of 2 to 40 mg/day. More recently, the beneficial effects of PCS on plasma cholesterol levels have been
249 questioned by the results of several RCTs performed in Europe and the US; these RCTs failed to find any

250 significant effect of PCS on plasma cholesterol levels in different clinical settings. The lack of cholesterol-
251 lowering efficacy has been confirmed for both Cuban sugar cane-derived PCS (102,103) and for PCS
252 extracted from different sources (104,105). In 2011, EFSA rejected a claim on the beneficial effects of PCS
253 for lack of evidence of a cause-effect relationship between PCS supplementation and cholesterol-lowering
254 (106).

255 Without consistent data on the cholesterol-lowering efficacy from different and independent research
256 groups, the use of PCS cannot be advised for cholesterol-lowering.

257257

258 **Red yeast rice**

259 Red yeast rice (RYR) is a fermented product of rice used for centuries in China for the preparation of rice
260 wine, as a flavor enhancer, as a food coloring and for therapeutic purposes as "aid for digestion and
261 circulation" (107). Fermentation of red rice by the yeast *Monascus purpureus* produces, among the others,
262 monacolin K, a monacolin that is structurally and functionally similar to lovastatin (107,108). Monacolin K
263 is able to inhibit HMGCoA reductase and cholesterol synthesis. The cholesterol-lowering efficacy of RYR
264 might be only in part attributable to monacolin K. Accordingly, RYR contains at least 10 different
265 monacolins, many of them with supposed HMGCoA reductase inhibitory activity. Furthermore, RYR
266 contains phytosterols, which are able to reduce intestinal cholesterol absorption, as well as fiber and niacin,
267 which exert cholesterol-lowering effects (108,109). Several trials have reported that RYR is effective and
268 safe in the treatment of patients with mild to moderate hypercholesterolemia. Placebo-controlled trials, some
269 of these lasting more than four years, have confirmed the cholesterol-lowering effect of RYR, with a
270 reduction of total cholesterol ranging from 16% to 31% and of LDL cholesterol from 22% to 32% (110).
271 The prescribed daily dose of RYR was variable in these trials, as well as the content of monacolin K of the
272 different RYR preparations (Table 7); in some of these trials, the dose of monacolin K exceeded 10 mg/day.
273 The first prospective double-blind placebo-controlled trial in the American population has been performed
274 in 1999 (111). Untreated patients with hyperlipidemia were randomized to receive either 2.4 g/day of RYR

275 or placebo for 12 weeks. At the end of the study, LDL cholesterol levels were significantly different
276 between the two groups compared to baseline; LDL cholesterol levels decreased by 39 ± 19 mg/dL (22%) in
277 the group receiving RYR and 5 ± 22 mg/dL (5%) in the placebo group. No adverse events were reported in
278 the two treatment arms (111). Additional clinical trials with RYR and meta-analyses (112-115) have
279 reported similar results in different study populations (Table 7). In a meta-analysis of thirteen randomized
280 placebo-controlled trials (113) including over 800 dyslipidemic patients, RYR reduced significantly LDL
281 cholesterol levels by 34 mg/dL compared to placebo; the cholesterol-lowering effect of RYR was neither
282 related to the dose and the duration of the nutraceutical supplementation nor it was associated with
283 significant side effects.

284 Similar results have been reported in other meta-analyses (112,114,115), confirming the cholesterol-
285 lowering efficacy of RYR and its good safety profile. In particular, a meta-analysis by Gerard et al. (114)
286 showed that the incidence of muscle, hepatic and renal adverse events was comparable between RYR and
287 placebo; overall, the clinical relevance of the possible adverse events of RYR were moderate, but it must be
288 underlined also the incomplete reporting of safety data in most individual trials included in this meta-
289 analysis (114).

290 Randomized trials have investigated the safety profile of RYR in patients who discontinued or refused
291 treatment with statins. RYR tolerability was compared with that of pravastatin in patients with a history of
292 statin-induced myalgia (116). Comparable LDL cholesterol reductions (30% and 27% in the RYR group and
293 in the pravastatin group, respectively) were achieved in both treatment groups, with also a low prevalence of
294 myalgias (5% and 9% in the RYR group and in the pravastatin group, respectively). In patients with statin
295 intolerance, supplementation with 3.6 g/day of RYR reduced plasma LDL cholesterol levels by 27%
296 compared to placebo, with a comparable safety profile between RYR and placebo (117). Particularly, pain
297 scale, serum creatine phosphokinase and liver enzyme levels did not differ in the two groups.

298 The impact of RYR on cardiovascular prognosis has been studied in the “China Coronary Secondary
299 Prevention Study” (118); this trial recruited 4870 patients with previous myocardial infarction and moderate

300 hypercholesterolemia, randomized to receive either *Xuenzhikang* (i.e., a purified extract of RYR containing
301 5-6.4 mg of monacolin K) or placebo for 5 years. *Xuenzhikang* reduced plasma LDL cholesterol levels by
302 20% and the risk of coronary heart disease events by 45% compared to placebo. Moreover, treatment with
303 *Xuenzhikang* also reduced significantly total mortality by 33%, cardiovascular mortality by 30% and
304 coronary revascularizations by 33%, with a comparable safety profile to placebo. Improvement of
305 endothelial function following RYR supplementation (119) further supports the possible cardiovascular
306 protective effect of RYR. The “Task Force for the management of dyslipidemias of the European Society of
307 Cardiology and the European Atherosclerosis Society” included RYR among those nutraceuticals with a
308 documented cholesterol-lowering activity (1).

309 On the basis of the quality and consistency of the data present in the literature in 2011, EFSA endorsed the
310 cause-effect relationship between use of RYR and maintenance of an adequate plasma LDL cholesterol
311 concentration in the general adult population; this effect would be reached with a dose of 10 mg/day of
312 monacolin K. Monacolin K is subjected to the same restrictions of lovastatin. In 2007, a claim by FDA
313 underlined the potential risks arising from online shopping of products containing RYR. Since 2007, FDA
314 did not release further advices on this topic (Table 2). In 2016, the Joint Commission of Experts of the
315 Federal Office of Consumer Protection and Food Safety (BVL) and the Federal Institute for Drugs and
316 Medical Devices (BfArM) in Germany has decided that products with a monacolin K dose of 5 mg per day
317 have a significant pharmacological/metabolic action and therefore should be classified as drugs.
318 Safety of different preparations containing RYR is debated, in part because composition of products
319 containing RYR is quite variable (120). For instance, commercial preparations labeled as containing 600 mg
320 of RYR per capsule, have been reported to contain variable amounts of monacolin K, ranging from 0.31 to
321 11.15 mg/capsule. Moreover, some RYR preparations contained citrinin (121), a mycotoxin with possible
322 renal toxicity. Therefore, the use of commercial preparations of RYR should be supported by adequate
323 demonstration of purity, safety and cholesterol-lowering efficacy.

324 On the basis of current knowledge, the use of RYR preparations containing a monacolin K dose ≤ 10 mg/day
325 can be advised in patients with mild to moderate cardiovascular risk and LDL cholesterol levels exceeding
326 th recommended therapeutic targets by 20-25% or less, despite adequate lifestyle changes have been
327 implemented (Table 3).

328328

329 **Berberine**

330 Berberine (BBR) is an isoquinoline alkaloid that is extracted from different plants, including *Berberis*
331 *vulgaris*, *Coptis chinensis*, *Berberis aristata* (122). BBR has anti-microbial, immune-modulatory, anti-
332 tumoral and metabolic effects (122). Additional favorable effects of BBR on cardiovascular system have
333 been proposed, considering that BBR promotes vasodilation, reduces the risk of congestive heart failure,
334 cardiac hypertrophy and arrhythmias (123). The cholesterol-lowering effect of BBR have been related to
335 different mechanisms of action. BBR promotes an increased expression and half life of the LDLR on the
336 hepatocyte surface (124); the transcriptional activity of the LDLR promoter is increased by BBR-induced
337 stimulation of the activation of JNK/c-jun. Also, LDLR mRNA is stabilized by ERK modulation (125).
338 Overall, all these effects promote an increased expression of the LDLR. In addition, BBR reduces the
339 expression of PCSK9 in vitro; because PCSK9 promotes lysosomal degradation of the LDLR, BBR-induced
340 PCSK9 inhibition might increase LDLR availability (126). Finally, BBR-induced activation of AMPK,
341 which in turn inactivates HMGCoA reductase (127), may have a role in cholesterol- and triglyceride-
342 lowering.

343 A study evaluating the effect of BBR in patients with hypercholesterolemia has shown significant
344 cholesterol- and triglyceride-lowering effects of BBR, with 25% and 35% reductions of plasma LDL
345 cholesterol and triglyceride levels, respectively (125); these effects were more pronounced in patients not
346 receiving other lipid-lowering drugs.

347 The lipid-lowering effects of BBR have been evaluated in three meta-analyses (128-130, Table 8). Dong et
348 al. (128,129) performed two meta-analyses of trials in patients with hypercholesterolemia and/or type 2

349 diabetes. The dose of BBR used in the different trials ranged from 0.5 g to 1.5 g/day. These meta-analyses
350 reported similar findings: BBR was associated with a 25 mg/dL decrease of plasma LDL cholesterol levels,
351 along with a significant reduction of plasma triglyceride level and a mild but significant increase of plasma
352 HDL cholesterol concentrations (Table 8).

353 The lipid-lowering efficacy of BBR was compared with that of simvastatin. In patients with
354 hypercholesterolemia, a 2-month treatment with either BBR, simvastatin or their combination, reduced
355 plasma total cholesterol, LDL cholesterol and triglyceride levels (131). Combination therapy reduced plasma
356 LDL cholesterol levels compared to the individual active treatments. Moreover, adding BBR to simvastatin
357 improved the mild statin-induced triglyceride-lowering of simvastatin alone (131). Possible side effects of
358 BBR emerged mostly in those trials using the highest doses of BBR; side effects included constipation,
359 diarrhea, abdominal distension and bitter taste in the mouth (129). Repeated oral administration of BBR
360 reduced the CYP2D6, CYP2D9 and CYP3A4 cytochrome activity in healthy subjects (132); thus, possible
361 interactions between BBR and drugs that use the same degradation pathways need to be considered.

362 Although results from intervention studies with BBR are quite consistent, it should be noted that almost all
363 interventional trials with BBR have been performed in Asian populations, that makes results'
364 generalizability difficult. Moreover, bioavailability of the different BBR preparations is a matter of debate.
365 Accordingly, the intestinal absorption of BBR is often minimal and with a wide inter-individual variability;
366 this issue could be responsible for a possible variability in the lipid-lowering efficacy of the different BBR
367 preparations.

368 Neither EFSA nor FDA have released yet specific claims on the cholesterol-lowering efficacy and safety of
369 BBR.

370 Based on current knowledge, if the results observed in Asian populations would be confirmed in other ethnic
371 groups, the use of BBR at a dose of 0.5-1.5 g/day could be advised in:

372 1) patients at mild to moderate cardiovascular risk with LDL cholesterol levels exceeding recommended
373 therapeutic goals by 20% or less, despite lifestyle changes have been implemented; 2) patients with mild to

374 moderate hypercholesterolemia and metabolic syndrome, in particular those with modest increases in
375 triglycerides or initial dysglycemia, possibly in combination with a statin; 3) patients with different levels of
376 risk in which there is a clear and documented intolerance to multiple statins or who refuse statin treatment
377 (Table 3).

378378

379 **Nutraceutical combinations**

380 Evidence reporting the cholesterol-lowering efficacy of different nutraceuticals has raised considerable
381 interest on this topic and prompted the development of novel preparations containing multiple nutraceuticals
382 with the aim to reach greater total and LDL cholesterol reductions.

383 The possibility to combine different nutraceuticals arises from two main speculative assumptions: 1) to
384 exploit the possible complementary lipid-lowering effects of each nutraceutical; 2) to reduce nutraceutical
385 doses in order to ensure tolerability while maintaining the lipid-lowering efficacy. To date, few RCTs have
386 been performed to support this assumptions.

387 The effect of combining fiber and phytosterols has been presented in a review of interventional studies, in
388 normolipidemic and moderately hypercholesterolemic individuals (133); an average reduction of plasma
389 total and LDL cholesterol levels of 8 and 11%, respectively, has been reported. The variety of fiber
390 supplements combined with phytosterols strongly affects the cholesterol-lowering efficacy. In addition, two
391 studies comparing the effect of the individual components versus their combination, revealed a slightly
392 higher cholesterol-lowering effect of the nutraceutical combination (134,135).

393 The combination of phytosterols and RYR did not provide an additional cholesterol-lowering effect
394 compared to the individual nutraceuticals (136).

395 The combination of RYR, BBR, PCS, astaxanthin (ASX), coenzyme Q10 (CoQ10) and folic acid (FA)
396 reduced plasma LDL cholesterol levels by 25%, without relevant side effects (137). This combination
397 reduced total cholesterol, LDL cholesterol and triglycerides in patients with hypercholesterolemia (138);
398 moreover, the same nutraceutical combination reduced HOMA index, suggesting a possible positive effect

399 on insulin sensitivity. Additional studies have been performed using the combination of
400 RYR/BBR/PCS/ASX/CoQ10/FA; specifically, patients with polygenic hypercholesterolemia, coronary
401 artery disease, statin intolerance, and children with either heterozygous familial hypercholesterolemia or
402 familial combined hyperlipidemia have been treated with this nutraceutical combination (139-145). Overall,
403 these studies confirmed the LDL cholesterol-lowering efficacy of the nutraceutical combination (from -15%
404 to 32%), with a greater cholesterol reduction in patients with higher pre-treatment LDL cholesterol levels. A
405 recent systematic review and meta-analysis of RCTs showed that the combination of
406 RYR/BBR/PCS/ASX/CoQ10/FA was associated with significant reductions of plasma total cholesterol
407 (-26.15 mg/dL), LDL cholesterol (-23.85 mg/dL), triglyceride (-13.83 mg/dL) and glucose levels (-2.59
408 mg/dL), and a modest but significant increase of plasma HDL cholesterol levels (2.53 mg/dL) (146).
409 Finally, small sample size studies have shown that the same nutraceutical combination was able to improve
410 endothelial function, aortic stiffness, endothelial injury and low-grade systemic inflammation (138,139,147).
411 Although the use of nutraceutical combinations might have possible advantages in terms of efficacy and
412 tolerability, evidence is still lacking on the potential additive/synergistic cholesterol-lowering effects of the
413 different nutraceuticals. Finally, the cholesterol-lowering benefit provided by the addition of PCS to any
414 nutraceutical combination is questionable.

415415

416 **Common issues of nutraceutical supplementation**

417 Although health benefits may arise from the use of different nutraceuticals with cholesterol-lowering
418 activity, their use might be also associated with possible risks, some of which are common to all
419 nutraceuticals whereas other risks are related to specific nutraceuticals.

420 Single-center design, short duration of supplementation and small sample size of most trials testing the
421 cholesterol-lowering efficacy of nutraceuticals are the main limitations. Hence, despite a number of meta-
422 analyses have been published confirming the beneficial influence of some nutraceuticals on lipid profile,
423 results of larger multicenter trials are desirable.

424 The independent buying and use of nutraceuticals might encourage patients under pharmacological
425 treatment to reduce or discontinue medications without a prior consult with physicians. In agreement with
426 this possibility, propensity to self-treatment and poor compliance to drug therapy has been recorded among
427 statin-treated patients who were informed on the possible beneficial effects of phytosterols (148-149).
428 Overall, the use of cholesterol-lowering nutraceuticals should not be considered as the “safe alternative” to
429 pharmacological intervention. This is particularly true in patients with genetic forms of
430 hypercholesterolemia and in other categories of patients at high or very high cardiovascular risk.

431 Another point to consider is that the cost of all fortified foods is far higher than that of non-fortified foods.
432 In 2008, EFSA reported that the cost/kg of plant sterols-enriched products can be up to 4-times higher than
433 that of non-enriched products (150). Similarly, the cost of products containing RYR and BBR is higher than
434 that of generic statins. Hence, if we consider the significant relationship between socioeconomic status and
435 dietary habits (151,152), the cost of most nutraceuticals can potentially interfere with their regular
436 purchasing and, consequently, with adherence and persistence to supplementation. This is a crucial point,
437 because as for cholesterol-lowering drugs, the therapeutic effect of nutraceuticals is expected to be closely
438 related to their regular use. Finally, the large and uncontrolled availability of nutraceutical preparations (e.g.,
439 supermarkets, e-commerce, drugstores) and the possibility that their use may be suggested by physicians,
440 nutritionists, dietitians, but also friends, relatives, or decided upon by the patients themselves might
441 predispose to the risk of incorrect consumption of these preparations and to the consequent side effects. This
442 risk might be higher for those nutraceuticals with "pharmacological" properties.

443 This statement highlights the need for a close collaboration between physicians, nutritionists, health care
444 professionals and patients in order to prevent the widespread improper and uncontrolled use of
445 nutraceuticals. In order to promote a safe and rational use of specific nutraceuticals, competent authorities
446 and caregivers should ensure careful monitoring of prescriptions, self-medications, the adequacy of doses
447 and compliance to nutraceutical supplementation. A key role in many of these processes should be played by
448 physicians, that should be aware of the possible risks of an incorrect use of cholesterol-lowering

449 nutraceuticals; however, they should also consider the potential benefit of a controlled use of single
450 nutraceuticals or rational combinations of nutraceuticals.

451451

452 **Conclusions**

453 Based on current literature, the cholesterol-lowering effect of some nutraceuticals (fiber, phytosterols, RYR)
454 is consistent and supported by a good level of scientific evidence (Table 9). Therefore, their use may be
455 advised in some particular categories of patients, as reported in Table 3. With regard to BBR, there is
456 sufficient evidence showing significant cholesterol-lowering effects, although these effects emerged from
457 interventional studies carried out almost exclusively in Asian populations, thus making these results difficult
458 to be generalized to other ethnic groups (Table 9). Data on the cholesterol-lowering effects of soy are
459 conflicting and, therefore, the strength of the recommendation is quite low, whereas the scientific evidence
460 is inconclusive for PCS (Table 9). Among the different nutraceuticals combinations, there is evidence
461 supporting the cholesterol-lowering efficacy and safety of low doses of RYR/BBR/PCS/ASX(CoQ10/FA;
462 however, on the basis of the available data, there is still no demonstration of an additive/synergistic
463 cholesterol-lowering effect of the single nutraceuticals used in this combination.

464 Therefore, the most relevant conclusions of this statement may be synthesized as follows:

- 465 1) On the basis of data present in the literature some nutraceuticals (added fiber, phytosterols, red yeast
466 rice) may help control hypercholesterolemia;
- 467 2) Of course, the above nutraceuticals may be of help only in subjects who do not yet need
468 pharmaceutical treatments, or in addition to drug therapy.

469469

Table 1. Meta-analyses and randomized controlled trials in humans on the lipid-lowering effects of different types of fiber

Fiber	Type of study	Subjects (Number, Type)	Average dose (range)	Mean duration (range)	Observed effects	Ref.
β-glucan (oats)	Meta-analysis of 25 RCT	n:1600 Healthy subjects Hypercholesterolemia Diabetes mellitus	5.0 g/day (2-30 g/day)	6 weeks (2-12 weeks)	↓ LDL-C: -6.2 mg/dl No effect on TG and HDL-C	(28)
	Meta-analysis of 28 RCT	n:2529 Healthy subjects Hypercholesterolemia Type 2 Diabetes	(3-12.4 g/day)	2-12 weeks	↓ LDL-C: -9.6 mg/dl No effect on TG and HDL-C	(29)
<i>Psillyum</i>	Meta-analysis of 17 RCT	n:757 Healthy subjects Hypercholesterolemia	9.1 g/day (2-30 g/day)	7 weeks (2-56 weeks)	↓ LDL-C: -10 mg/dl No effect on TG and HDL-C	(28)
	Meta-analysis of 21 RCT	n: 1717 Hypercholesterolemia	(3-20 g/day)	(2-26 weeks)	↓ LDL-C: - 11 mg/dl No effect on TG	(30)
	RCT	n:187 Hypercholesterolemia on pharmacological treatment	14 g/day	8 weeks	↓ LDL-C: -11 mg/dl (-6%) ↓ TG: -20 mg/dl (-17%) No effect on HDL-C	(31)
Pectin	Meta-analysis of 7 RCT	n: 277 Healthy subjects Hypercholesterolemia Diabetes mellitus	4.7 g/day (2-30 g/day)	5 weeks (4-6 weeks)	↓ LDL-C: -9.9 mg/dl No effect on TG and HDL-C	(28)
Guar gum	Meta-analysis of 18 RCT	n: 356 Healthy subjects Hypercholesterolemia Diabetes mellitus	17.5 g/day (2-30 g/day)	66 days (4-24 weeks)	↓ LDL-C: -22 mg/dl No effect on TG and HDL-C	(28)
Chitosan	Meta-analysis of 9 RCT	n:1219 Healthy subjects	3.7 g/day (0.24-15 g/day)	8.3 weeks (4-24 weeks)	↓ LDL-C: -6.2 mg/dl ↑ HDL-C: 1.2 mg/dl ↓ TG: -11 mg/dl	(32)
Glucmannan	Meta-analysis of 14 RCT	n: 531 Healthy subjects Hypercholesterolemia Diabetes mellitus	(1.2-15.1 g/day)	(3-16 weeks)	↓ LDL-C: -16 mg/dl ↓ TG: -11 mg/dl No effect on HDL-C	(33)
HPMC	RCT	n:52 Hypercholesterolemia	A: 5 g/day B: 15 g/day	8 weeks	A: ↓ LDL-C: -14 mg/dl No effect on TG and HDL-C B: ↓ LDL-C: -14 mg/dl No effect on TG and HDL-C	(34)
	RCT	n:13 Hypercholesterolemia on pharmacological treatment	5 g/day	4 weeks	↓ LDL-C: (-10%) No effect on TG and HDL-C	(35)

↑: increase, ↓: reduction, HDL-C: HDL-cholesterol, LDL-C: LDL-cholesterol, HPMC: hydroxypropyl-methylcellulose, TG: triglycerides, RCT: randomized controlled trials.

471

472

Table 2. Claims released by EFSA and FDA on nutraceuticals with cholesterol-lowering activity

Nutraceutical	Effective dose evaluated in the claim	EFSA	FDA
Fiber:			
β -glucan*	≥ 3 g/day	Reduction of LDL-C	Reduction del LDL-C Reduction of CHD risk
Chitosan	3 g/day	Maintenance of normal levels of LDL-C	-
Glucomannan	4 g/day	Maintenance of normal levels of LDL-C	-
Guar gum	10 g/day	Maintenance of normal levels of LDL-C	-
HPMC	5 g/day	Maintenance of normal levels of LDL-C	-
Pectin	6 g/day	Maintenance of normal levels of LDL-C	-
<i>Psyllium</i>	≥ 7 g/day	-	Reduction of LDL-C
Phytosterols	3 g/day	Reduction of LDL-C	Reduction of LDL-C
Soy derivatives	25 g/day	-	Reduction of CV risk
Policosanol	-	-	-
Red Yeast Rice	10 mg/day of monacolin K	Maintenance of normal levels of LDL-C	Monacolin K has the same restrictions to which is subjected lovastatin.
Berberine	-	-	-

* From oats and barley, CHD: coronary heart disease, LDL-C: LDL cholesterol, CV: cardiovascular, HPMC: hydroxypropylmethylcellulose.

473

474

475

476

477

Table 3. Advantages, disadvantages and possible indications of cholesterol-lowering nutraceuticals

	Advantage	Disadvantages	Possible indication
Fiber	<ul style="list-style-type: none"> - LDL-C reduction by 4-14% - Effect on other CV risk factors - Relatively low-cost 	<ul style="list-style-type: none"> Intestinal discomfort for excessive doses 	<ul style="list-style-type: none"> - General population that fails to increase fiber intake with diet alone - Patients with mild hypercholesterolemia and low to moderate cardiovascular risk * - Patients with mild hypercholesterolemia and metabolic syndrome
Phytosterols	<ul style="list-style-type: none"> - LDL-C reduction by 8-10% - No interaction with lipid-lowering drugs 	<ul style="list-style-type: none"> - Self purchasing by patients and risk of no medical supervision - Possible excessive intake with the risk of reduced absorption of fat soluble vitamins - High cost 	<ul style="list-style-type: none"> - Patients with mild hypercholesterolemia and low to moderate cardiovascular risk * - Patients with intolerance to multiple statins - In addition to drug therapy for patients who do not reach optimal levels of LDL-C
Soy products	<ul style="list-style-type: none"> - LDL-C reduction by 4-13% 	<ul style="list-style-type: none"> - Self purchasing by the patient - Risk of allergies - High cost 	<ul style="list-style-type: none"> - General population - Patients with mild hypercholesterolemia and low to moderate cardiovascular risk *
Red Yeast Rice	<ul style="list-style-type: none"> - LDL-C reduction by 16-25% - Good safety profile - Reduction of cardiovascular risk 	<ul style="list-style-type: none"> - Variability of composition and purity of OTC products - Self purchasing by patients and risk of no medical supervision - Higher cost compared to generic statins - Possible side effects at high doses 	<ul style="list-style-type: none"> - Patients with mild to moderate hypercholesterolemia and low to moderate cardiovascular risk **
Berberine [§]	<ul style="list-style-type: none"> - LDL-C reduction by 20% - Better safety profile in patients with intolerance to multiple statins - Favorable effect on TG, HDL-C and blood glucose 	<ul style="list-style-type: none"> - Variability of intestinal absorption - Self purchasing by patients and risk of no medical supervision - Higher cost compared to generic statins 	<ul style="list-style-type: none"> - Patients with mild to moderate hypercholesterolemia and low to moderate CV risk *** - Patients with mild hypercholesterolemia and metabolic syndrome[†] - Patients with intolerance to multiple statins - In addition to drug therapy for patients who do not reach optimal levels of LDL-C

* patients requiring a reduction of LDL cholesterol by up to 10-15%, ** patients requiring a reduction of LDL cholesterol by up to 20-25%, *** patients requiring a reduction of LDL cholesterol by up to 20%, § studies performed almost exclusively in Asian populations and therefore not easily transferable to other populations, † Even in combination with a statin, in patients with modest increase in serum triglycerides and/or blood glucose. HDL-C: HDL cholesterol, LDL-C: LDL cholesterol, CV: cardiovascular; TG: triglycerides; OTC: over the counter.

478

479

Table 4. Meta-analyses of randomized controlled trials in humans on the lipid-lowering effects of phytosterols

Type of study	Subjects (Number, Type)	Average dose (range)	Mean duration (range)	Observed effect	Ref.
Meta-analysis of 49 RCT	n: >4500 Healthy subjects Hypercholesterolemia	(0.3-9 g/day)	(3-26 weeks)	↓ LDL-C: - 12 mg/dl	(46)
Meta-analysis of 20 RCT	n: 1273 Healthy subjects Hypercholesterolemia	2.08 g/day (0.45-3.2 g/day)	(2-52 weeks)	↓ LDL-C: -14 mg/dl (-6/-15%) No effect on TG and HDL-C	(47)
Meta-analysis of 84 RCT	n: 6805 Healthy subjects Hypercholesterolemia	2.15 g/day (0.45–9 g/day)	(21-182 days)	↓ LDL-C: -13 mg/dl (-8.8%)	(48)
Meta-analysis of 41 RCT	n: 2084 Healthy subjects Hypercholesterolemia	1.6 g/day (0.3-3.2 g/day)	28 days (21-315 days)	↓ LDL-C: -13 mg/dl (-8.5%) No effect on HDL-C	(49)
Meta-analysis of 124 RCT	Healthy subjects Hypercholesterolemia	2.1 g/day (0.2–9 g/day)	At least 2 weeks	↓ LDL-C: -6/12%.	(50)
Meta-analysis of 6 RCT*	n: 453 Familial Hypercholesterolemia	(1.6-2 g/day)	(4-8 weeks)	↓ LDL-C: -25 mg/dl No effect on TG and HDL-C	(51)
Meta-analysis of 5 RCT	n: 148 Diabetes mellitus	(1.8-3 g/day)	(3-12 weeks)	↓ LDL-C: -12 mg/dl No effect on TG and HDL-C	(52)
Meta-analysis of 12 RCT	n: 935 Hypercholesterolemia	(0.8-4 g/day)	(3-4 weeks)	↓ TG: -11 mg/dl (-6%) No effect on HDL-C	(53)

*2 studies with supplementation of stanols and 5 studies with supplementation of sterols, ↑: increase, ↓: reduction, HDL-C: HDL cholesterol, LDL-C: LDL cholesterol, TG: triglycerides, RCT: randomized controlled trials.

Table 5. Meta-analyses of randomized controlled trials in humans on the lipid-lowering effects of soy

Type of study	Subjects (Number, Type)	Average dose (range)	Mean duration (range)	Observed effect	Ref.
Meta-analysis of 38 RCT	n: 743 Healthy subjects Hypercholesterolemia	Soy proteins 47 g/day (18-124 g/day)	-	↓ LDL-C: -12.9% ↓ TG: -10.5% ↑ HDL-C: 2.4%	(67)
Meta-analysis of 10 RCT	n: 959 Healthy subjects Hypercholesterolemia	Soy proteins (19-60 g/day) Isoflavones (1-95 mg/day)	At least 14 days	↓ LDL-C: -6.56 mg/dl ↑ HDL-C: 1.16 mg/dl	(69)
Meta-analysis of 8 RCT	n: 639 Healthy subjects Hypercholesterolemia	Soy proteins (25-100 g/day) Isoflavones (3-132 mg/day)	-	↓ LDL-C: -5.79 mg/dl	(70)
Meta-analysis of 23 RCT	n:1833 Healthy subjects Hypercholesterolemia	Isoflavones (3-185 mg/day)	(4-26 weeks)	↓ LDL-C: -5.25% ↓ TG: -7.27% ↑ HDL-C: 3.03%	(71)
Meta-analysis of 10 RCT	n: 1756 Healthy subjects Hypercholesterolemia	Soy proteins (20-106.2 g/day) Isoflavones (2-192.4 mg/day)	(3-52 weeks)	↓ LDL-C -4.25 mg/dl ↓ TG: -6.26 mg/dl ↑ HDL-C: 0.77 mg/dl	(72)
Meta-analysis of 10 RCT	n: 430 Healthy subjects Hypercholesterolemia	Soy proteins (25-133 g/day) Isoflavones (0-317.9 mg/day)	(3-14 weeks)	↓ LDL-C: -4.98% ↓ TG: -0.69% ↑ HDL-C: 3.00%	(73)
Meta-analysis of 30 RCT	n: 2913 Healthy Hypercholesterolemia	Soy proteins 26.9 g/day (15-40 g/day)	(4-52 weeks)	↓ LDL-C: -8.88 mg/dl (~6%) ↓ TG: -7.70 mg/dl ↑ HDL-C: 2.74 mg/dl	(74)
Meta-analysis of 43 RCT	Healthy subjects Hypercholesterolemia	Soy proteins <65 g/day	(4-18 weeks)	↓ LDL-C: from - 4.2 to -5.5% ↓ TG: -10.7% ↑ HDL-C: 3.2%	(75)
Meta-analysis of 8 RCT	n: 183 Type 2 Diabetes mellitus	Soy proteins (30-111 g/day) Isoflavones (0-132 mg/day)	(6-208 weeks)	↓ LDL-C: -11.6 mg/dl ↓ TG: -19.5 mg/dl ↑ HDL-C: 1.9 mg/dl	(76)
Meta-analysis of 14 RCT	Familial Hypercholesterolemia	-	-	↓ LDL-C: 4.6 mg/dl ↓ TG: -22 mg/dl ↑ HDL-C: 2.7 mg/dl	(51)

↑: increase, ↓: reduction, HDL-C: HDL cholesterol, LDL-C: LDL cholesterol, TG: triglycerides, RCT: randomized controlled trials.

516

517

Table 6. Meta-analyses and randomized controlled trials in humans on the lipid-lowering effects of policosanol

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

Type of study	Subjects (Number, Type)	Average dose (range)	Mean duration (range)	Observed effect	Ref.
Meta-analysis of 30 RCT	Healthy subjects Hypertension Hypercholesterolemia Type 2 Diabetes	12 mg (5–40 mg)	29.6 weeks (4–104 weeks)	↓ LDL-C: -23.7% ↓ TG: -12.45%; ↑ HDL-C: 10.6%	(101)
RCT	Hypercholesterolemia Familial Hypercholesterolemia	20 mg	12 weeks	HyperC: ↓ LDL-C: -6% ↓ HDL-C: -5.5% ↑ TG: 9.6% FH: ↑ LDL-C: 3% ↑ HDL-C: 2.5% ↓ TG: -9.8%	(102)
RCT	n: 143 Hypercholesterolemia Mixed hyperlipidemia	10 - 80 mg	12 weeks	↓ LDL-C: -2% to -9% ↓ TG: -10% to -20% ↑ HDL-C: 0.6% to 4.6%	(103)
RCT	n:40 Hypercholesterolemia	20 mg	8 weeks	↓ LDL-C: -7.7% ↓ TG: -1.3% ↓ HDL-C: -3.3%	(105)

↑: increase, ↓: reduction, HDL-C: HDL cholesterol, LDL-C: LDL cholesterol, TG: triglycerides, HyperC: Hypercholesterolemia, FH: Familial Hypercholesterolemia, RCT: randomized controlled trials.

Table 7. Meta-analyses of randomized controlled trials in humans on the lipid-lowering effects of red yeast rice

Type of study	Subjects (Number, Type)	Content of monacolin K	Mean duration (range)	Observed effect	Ref.
Meta-analysis of 93 RCT	n: 9625 Dyslipidemia	3-12.4 mg/day	8 weeks (4-24 weeks)	↓ LDL-C: -28 mg/dl ↓ TG: -36 mg/dl ↑ HDL-C: 5.8 mg/dl	(112)
Meta-analysis of 13 RCT	n: 804 Dyslipidemia	2-11.4 mg/day	12 weeks (4-24 weeks)	↓ LDL-C: -34 mg/dl ↓ TG: -20 mg/dl No effect on HDL-C	(113)
Meta-analysis of 20 RCT	n: 2811 Dyslipidemia, Type 2 Diabetes, CHD, Hypertensive	4.8-24 mg/day	23 weeks 4-168 weeks	↓ LDL-C: -39 mg/dl ↓ TG: -23 mg/dl ↑ HDL-C: 2.7 mg/dl	(114)
Meta-analysis of 21 RCT	n: 4558 Hypertensive	(RYR 1200-1800 mg/day)	4-234 weeks	↓ LDL-C: -24 mg/dl No effect on TG and HDL-C	(115)

↑: increase, ↓: reduction, HDL-C: HDL cholesterol, LDL-C: LDL cholesterol, CHD: coronary heart disease, RYR: red yeast rice, TG: triglycerides, RCT: randomized controlled trials.

Table 8. Meta-analyses of randomized controlled trials in humans on the lipid-lowering effects of berberine

Type of study	Subjects (Number, Type)	Average dose (range)	Mean duration (range)	Observed effect	Ref.
Meta-analysis of 14 RCT	n: 1068 Type 2 Diabetes	0.5-1.5 g/day	12 weeks (8-24 weeks)	↓ LDL-C: -13/-22 mg/dl ↓ TG: -19/-45 mg/dl ↑ HDL-C: 0.8/2.7 mg/dl	(128)
Meta-analysis of 11 RCT	n: 874 Dyslipidemia, Type 2 Diabetes	0.5-1.5 g/day	15 weeks (8-52 weeks)	↓ LDL-C: -25 mg/dl ↓ TG: -44 mg/dl ↑ HDL-C: 1.9 mg/dl	(129)
Meta-analysis of 6 RCT	n: 451 Dyslipidemia	0.6-1.5 g/day	11 weeks (8-17 weeks)	↓ LDL-C: -25 mg/dl ↓ TG: -35 mg/dl ↑ HDL-C: 2.7 mg/dl	(130)

↑: increase, ↓: reduction, HDL-C: HDL cholesterol, LDL-C: LDL cholesterol, TG: triglycerides, RCT: randomized controlled trials.

591
592

Table 9. LDL-C reduction, levels of evidence and strength of recommendation for different cholesterol-lowering nutraceuticals.

	Degree of LDL cholesterol reduction	Level of evidence	Strength of recommendation
Fiber	+	I	A
Phytosterols	+	I	A
Soy derivatives	+/-	II	C
Policosanol	-	VI	D
Red Yeast Rice	++	I	A
Berberin	++	*	*

Levels of evidence and strength of recommendation according to the Italian standard of care for diabetes (153):

Levels of evidence:

I: evidence obtained from multiple randomized controlled trials and/or from systematic reviews of randomized controlled trials;

II: evidence obtained from one randomized trial;

VI: *consensus* of experts.

Strength of recommendation:

A: strongly recommended;

C: basic uncertainty;

D: no recommendation.

* The level of evidence would be I, because supported by meta-analysis of interventional studies, and strength of recommendation A; however, because these studies were conducted almost exclusively in Asian populations, the data are not easily transferable to other ethnic groups.

593 **References**

594

- 595 1. Catapano AL, Graham I, De Backer G , Wiklund O, Chapman MJ, Drexel H, Hoes AV ,
596 Jennings CS , Landmesser U, Pedersen TR, Reiner Z, Riccardi G, Taskinen MR,
597 Tokgozoglul. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias : The
598 Task Force for the Management of Dyslipidaemias of the European Society of Cardiology
599 (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution
600 of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).
601 *Atherosclerosis*, 2016; 1-64.
- 602 2. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of
603 premature death from coronary heart disease continuous and graded? Findings in 356,222
604 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). *JAMA*, 1986;
605 256:2823-2828.
- 606 3. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease--the Framingham
607 Heart Study. *Can J Cardiol*, 1988; 4 Suppl A:5A-10A.
- 608 4. Naci H, Bruggs JJ, Fleurence R, Tsoi B, Toor H, Ades AE. Comparative benefits of statins in
609 the primary and secondary prevention of major coronary events and all-cause mortality: a
610 network meta-analysis of placebo-controlled and active-comparator trials. *Eur J Prev
611 Cardiol*, 2013; 20:641-657.
- 612 5. Rembold CM. To statin or to non-statin in coronary disease--considering absolute risk is the
613 answer. *Atherosclerosis*, 2007; 195:1-6.
- 614 6. Bruckert E, Ferrières J. Evidence supporting primary prevention of cardiovascular diseases
615 with statins: Gaps between updated clinical results and actual practice. *Arch Cardiovasc Dis*,
616 2014; 107:188-200.

- 617 7. Braamskamp MJ, Hutten BA, Wiegman A. Early initiation of statin treatment in children
618 with familial hypercholesterolaemia. *Curr Opin Lipidol*, 2015; 26:236-239.
- 619 8. Cholesterol Treatment Trialists' (CTT) Collaboration, Fulcher J, O'Connell R, Voysey M,
620 Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H,
621 Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent
622 C, Keech A. Efficacy and safety of LDL-lowering therapy among men and women: meta-
623 analysis of individual data from 174,000 participants in 27 randomised trials. *Lancet*, 2015;
624 385:1397-1405.
- 625 9. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis
626 BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzylo W, De Lucca P, Im K, Bohula EA,
627 Reist C, Wiviott SD, Tereshakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-
628 IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. *N*
629 *Engl J Med*, 2015; 372:2387-2397.
- 630 10. Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. *J*
631 *Lipid Res*, 2009; 50 Suppl:S172-177.
- 632 11. Schulz R, Schlüter KD, Laufs U. Molecular and cellular function of the proprotein
633 convertase subtilisin/kexin type 9 (PCSK9). *Basic Res Cardiol*, 2015; 110:4.
- 634 12. Smith CS, Cannon CP, McCabe CH, Murphy SA, Bentley J, Braunwald E. Early initiation
635 of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline
636 recommendations: observations from the Orbofiban in Patients with Unstable Coronary
637 Syndromes (OPUS-TIMI 16) trial. *Am Heart J*, 2005; 149:444-450.
- 638 13. Navarese EP, Kowalewski M, Andreotti F, van Wely M, Camaro C, Kolodziejczak M,
639 Gorny B, Wirianta J, Kubica J, Kelm M, de Boer MJ, Suryapranata H. Meta-analysis of
640 time-related benefits of statin therapy in patients with acute coronary syndrome undergoing
641 percutaneous coronary intervention. *Am J Cardiol*, 2014; 113:1753-1764.

- 642 14. Chapman K. Can people make healthy changes to their diet and maintain them in the long
643 term? A review of the evidence. *Appetite*, 2010; 54:433-441.
- 644 15. McRorie JW Jr. Evidence-Based Approach to Fiber Supplements and Clinically Meaningful
645 Health Benefits, Part 1: What to Look for and How to Recommend an Effective Fiber
646 Therapy. *Nutr Today*, 2015; 50:82-89.
- 647 16. Chutkan R, Fahey G, Wright WL, McRorie J. Viscous versus nonviscous soluble fiber
648 supplements: mechanisms and evidence for fiber-specific health benefits. *J Am Acad Nurse*
649 *Pract*, 2011; 24:476-487.
- 650 17. Vuksan V, Jenkins AL, Rogovik AL, Fairgrieve CD, Jovanovski E, Leiter LA. Viscosity
651 rather than quantity of dietary fibre predicts cholesterol-lowering effect in healthy
652 individuals. *Br J Nutr*, 2011; 106:1349-1352.
- 653 18. Assmann G, Buono P, Daniele A, Della Valle E, Farinaro E, Ferns G, Krogh V, Kromhout
654 D, Masana L, Merino J, Misciagna G, Panico S, Riccardi G, Rivellese AA, Rozza F,
655 Salvatore F, Salvatore V, Stranges S, Trevisan M, Trimarco B, Vetrani C. Functional foods
656 and cardiometabolic diseases* International Task Force for Prevention of Cardiometabolic
657 Diseases. *Nutr Metab Cardiovasc Dis*, 2014; 24:1272-1300.
- 658 19. Yang Y, Zhao LG, Wu QJ, Ma X, Xiang YB. Association between dietary fiber and lower
659 risk of all-cause mortality: a meta-analysis of cohort studies. *Am J Epidemiol*, 2015; 181:83-
660 91.
- 661 20. Moreno Franco B, León Latre M, Andrés Esteban EM, Ordovás JM, Casasnovas JA,
662 Peñalvo JL. Soluble and insoluble dietary fibre intake and risk factors for metabolic
663 syndrome and cardiovascular disease in middle-aged adults: the AWHs cohort. *Nutr Hosp*,
664 2014; 30:1279-1288.
- 665 21. Pereira MA, O'Reilly E, Augustsson K, Fraser GE, Goldbourt U, Heitmann BL, Hallmans
666 G, Knekt P, Liu S, Pietinen P, Spiegelman D, Stevens J, Virtamo J, Willett WC, Ascherio A.

- 667 Dietary fiber and risk of coronary heart disease: a pooled analysis of cohort studies. Arch
668 Intern Med, 2004; 164:370-376.
- 669 22. Bazzano LA, Thompson AM, Tees MT, Nguyen CH, Winham DM. Non-soy legume
670 consumption lowers cholesterol levels: a meta-analysis of randomized controlled trials. Nutr
671 Metab Cardiovasc Dis, 2011; 21:94-103.
- 672 23. Estruch R, Martínez-González MA, Corella D, Basora-Gallissá J, Ruiz-Gutiérrez V, Covas
673 MI, Fiol M, Gómez-Gracia E, López-Sabater MC, Escoda R, Pena MA, Diez-Espino J,
674 Lahoz C, Lapetra J, Sáez G, Ros E; PREDIMED Study Investigators. Effects of dietary fibre
675 intake on risk factors for cardiovascular disease in subjects at high risk. J Epidemiol
676 Community Health, 2009; 63:582-588.
- 677 24. Riccardi G, Rivellese AA. Effects of dietary fiber and carbohydrate on glucose and
678 lipoprotein metabolism in diabetic patients. Diabetes Care, 1991; 14:1115-1125.
- 679 25. Grooms KN, Ommerborn MJ, Pham do Q, Djoussé L, Clark CR. Dietary fiber intake and
680 cardiometabolic risks among US adults, NHANES 1999-2010. Am J Med, 2013; 126:1059-
681 1067.
- 682 26. Sette S, Le Donne C, Piccinelli R, Arcella D, Turrini A, Leclercq C; INRAN-SCAI 2005-6
683 Study Group. The third Italian National Food Consumption Survey, INRAN-SCAI 2005-06-
684 -part 1: nutrient intakes in Italy. Nutr Metab Cardiovasc Dis, 2011; 21:922-932.
- 685 27. Cust AE, Skilton MR, van Bakel MM, Halkjaer J, Olsen A, Agnoli C et al. Total dietary
686 carbohydrate, sugar, starch and fibre intakes in the European Prospective Investigation into
687 Cancer and Nutrition. Eur J Clin Nutr, 2009; 63:S37-S60.
- 688 28. Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering effects of dietary fiber: a
689 meta-analysis. Am J Clin Nutr, 1999; 69:30-42.
- 690 29. Whitehead A, Beck EJ, Tosh S, Wolever TM. Cholesterol-lowering effects of oat β -glucan:
691 a meta-analysis of randomized controlled trials. Am J Clin Nutr, 2014; 100:1413-1421.

- 692 30. Wei ZH, Wang H, Chen XY, Wang BS, Rong ZX, Wang BS, Su BH, Chen HZ. Time- and
693 dose-dependent effect of *psyllium* on serum lipids in mild-to-moderate
694 hypercholesterolemia: a meta-analysis of controlled clinical trials. *Eur J Clin Nutr*, 2009;
695 63:821-827.
- 696 31. Solà R, Bruckert E, Valls RM, Narejos S, Luque X, Castro-Cabezas M, Doménech G,
697 Torres F, Heras M, Farrés X, Vaquer JV, Martínez JM, Almaraz MC, Anguera A. Soluble
698 fibre (*Plantago ovata* husk) reduces plasma low-density lipoprotein (LDL) cholesterol,
699 triglycerides, insulin, oxidised LDL and systolic blood pressure in hypercholesterolaemic
700 patients: A randomised trial. *Atherosclerosis*, 2010; 211:630-637.
- 701 32. Jull AB, Ni Mhurchu C, Bennett DA, Dunshea-Mooij CA, Rodgers A. Chitosan for
702 overweight or obesity. *Cochrane Database Syst Rev*, 2008; 3:CD003892. doi:
703 10.1002/14651858.CD003892.pub3.
- 704 33. Sood N, Baker WL, Coleman CI. Effect of glucomannan on plasma lipid and glucose
705 concentrations, body weight, and blood pressure: systematic review and meta-analysis. *Am J*
706 *Clin Nutr*, 2008; 88:1167-1175.
- 707 34. Reppas C, Swidan SZ, Tobey SW, Turowski M, Dressman JB.
708 Hydroxypropylmethylcellulose significantly lowers blood cholesterol in mildly
709 hypercholesterolemic human subjects. *Eur J Clin Nutr*, 2009; 63:71-77.
- 710 35. Maki KC, Carson ML, Miller MP, Anderson WH, Turowski M, Reeves MS, Kaden V,
711 Dicklin MR. Hydroxypropylmethylcellulose lowers cholesterol in statin-treated men and
712 women with primary hypercholesterolemia. *Eur J Clin Nutr*, 2009; 63:1001-1007.
- 713 36. De Natale C, Annuzzi G, Bozzetto L, Mazzarella R, Costabile G, Ciano O, Riccardi G,
714 Rivellese AA. Effects of a plant-based high-carbohydrate/high-fiber diet versus high-
715 monounsaturated fat/low-carbohydrate diet on postprandial lipids in type 2 diabetic patients.
716 *Diabetes Care* 2009; 32:2168-2173.

- 717 37. Giacco R, Costabile G, Della Pepa G, Anniballi G, Griffo E, Mangione A, Cipriano P,
718 Viscovo D, Clemente G, Landberg R, Pacini G, Rivellese AA, Riccardi G. A whole-grain
719 cereal-based diet lowers postprandial plasma insulin and triglyceride levels in individuals
720 with metabolic syndrome. *Nutr Metab Cardiovasc Dis*, 2014; 24:837-844.
- 721 38. EFSA Panel on Dietetic Products, Nutrition, and Allergies (NDA); Scientific Opinion on
722 Dietary Reference Values for carbohydrates and dietary fibre. *EFSA Journal* 2010; 8:1462
723 [77 pp.]. doi:10.2903/j.efsa.2010.1462. Available online: www.efsa.europa.eu.
- 724 39. Dahl WJ, Stewart ML. Position of the Academy of Nutrition and Dietetics: Health
725 Implications of Dietary Fiber. *J Acad Nutr Diet*, 2015; 115:1861-1870.
- 726 40. Gylling H, Plat J, Turley S, Ginsberg HN, Ellegård L, Jessup W, Jones PJ, Lütjohann D,
727 Maerz W, Masana L, Silbernagel G, Staels B, Borén J, Catapano AL, De Backer G,
728 Deanfield J, Descamps OS, Kovanen PT, Riccardi G, Tokgözoğlu L, Chapman MJ;
729 European Atherosclerosis Society Consensus Panel on Phytosterols. Plant sterols and plant
730 stanols in the management of dyslipidaemia and prevention of cardiovascular disease.
731 *Atherosclerosis*, 2014; 232:346-360.
- 732 41. Chen ZY, Ma KY, Liang Y, Peng C, Zuo Y. Role and classification of cholesterol-lowering
733 functional foods. *Journal of Functional Foods*, 2011; 3:61-69.
- 734 42. Andersson SW, Skinner J, Ellegård L, Welch AA, Bingham S, Mulligan A, Andersson H,
735 Khaw KT. Intake of dietary plant sterols is inversely related to serum cholesterol
736 concentration in men and women in the EPIC Norfolk population: a cross-sectional study.
737 *Eur J Clin Nutr*, 2004; 58:1378-1385.
- 738 43. Klingberg S, Ellegård L, Johansson I, Hallmans G, Weinehall L, Andersson H, Winkvist A.
739 Inverse relation between dietary intake of naturally occurring plant sterols and serum
740 cholesterol in northern Sweden. *Am J Clin Nutr*, 2008; 87:993-1001.

- 741 44. Wang P, Chen YM, He LP, Chen CG, Zhang B, Xue WQ, Su YX. Association of natural
742 intake of dietary plant sterols with carotid intima-media thickness and blood lipids in
743 Chinese adults: a cross-section study. *PLoS One*, 2012;7:e32736.
- 744 45. Mannarino E, Pirro M, Cortese C, Lupattelli G, Siepi D, Mezzetti A, Bertolini S, Parillo M,
745 Fellin R, Pujia A, Averna M, Nicolle C, Notarbartolo A. Effects of a phytosterol-enriched
746 dairy product on lipids, sterols and 8-isoprostane in hypercholesterolemic patients: a
747 multicenter Italian study. *Nutr Metab Cardiovasc Dis*. 2009 Feb;19:84-90.
- 748 46. Abumweis SS, Barake R, Jones PJ. Plant sterols/stanols as cholesterol lowering agents: A
749 meta-analysis of randomized controlled trials. *Food Nutr Res*, 2008; 52.
- 750 47. Wu T, Fu J, Yang Y, Zhang L, Han J. The effects of phytosterols/stanols on blood lipid
751 profiles: a systematic review with meta-analysis. *Asia Pac J Clin Nutr*, 2009;18:179-186.
- 752 48. Demonty I, Ras RT, van der Knaap HC, Duchateau GS, Meijer L, Zock PL, Geleijnse JM,
753 Trautwein EA. Continuous dose-response relationship of the LDL-cholesterol-lowering
754 effect of phytosterol intake. *J Nutr*, 2009; 139:271-284.
- 755 49. Ras RT, Hiemstra H, Lin Y, Vermeer MA, Duchateau GS, Trautwein EA. Consumption of
756 plant sterol-enriched foods and effects on plasma plant sterol concentrations--a meta-
757 analysis of randomized controlled studies. *Atherosclerosis*, 2013; 230:336-346.
- 758 50. Ras RT, Geleijnse JM, Trautwein EA. LDL-cholesterol-lowering effect of plant sterols and
759 stanols across different dose ranges: a meta-analysis of randomised controlled studies. *Br J*
760 *Nutr*, 2014; 112:214-219.
- 761 51. Malhotra A, Shafiq N, Arora A, Singh M, Kumar R, Malhotra S. Dietary interventions
762 (plant sterols, stanols, omega-3 fatty acids, soy protein and dietary fibers) for familial
763 hypercholesterolaemia. *Cochrane Database Syst Rev*, 2014; 6:CD001918. doi:
764 10.1002/14651858.CD001918.pub3.

- 765 52. Baker WL, Baker EL, Coleman CI. The effect of plant sterols or stanols on lipid parameters
766 in patients with type 2 diabetes: a meta-analysis. *Diabetes Res Clin Pract*, 2009; 84:e33-e37.
- 767 53. Demonty I, Ras RT, van der Knaap HC, Meijer L, Zock PL, Geleijnse JM, Trautwein EA.
768 The effect of plant sterols on serum triglyceride concentrations is dependent on baseline
769 concentrations: a pooled analysis of 12 randomised controlled trials. *Eur J Nutr*, 2013;
770 52:153-160.
- 771 54. Ketomaki A, Gylling H, Miettinen TA. Effects of plant stanol and sterol esters on serum
772 phytosterols in a family with familial hypercholesterolemia including a homozygous subject.
773 *J Lab Clin Med*, 2004; 143:255-262.
- 774 55. Musa-Veloso K, Poon TH, Elliot JA, Chung C. A comparison of the LDL-cholesterol
775 lowering efficacy of plant stanols and plant sterols over a continuous dose range: results of a
776 meta-analysis of randomized, placebo-controlled trials. *Prostaglandins Leukot Essent Fatty*
777 *Acids*, 2011; 85:9-28.
- 778 56. Lichtenstein AH, Deckelbaum RJ. AHA Science Advisory. Stanol/sterol ester-containing
779 foods and blood cholesterol levels. A statement for healthcare professionals from the
780 Nutrition Committee of the Council on Nutrition, Physical Activity, and Metabolism of the
781 American Heart Association. *Circulation*, 2001; 103:1177-1179.
- 782 57. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P,
783 Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A,
784 Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syv anne M, Scholte op Reimer
785 WJ, Vrints C, Wood D, Zamorano JL, Zannad F; European Association for Cardiovascular
786 Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG).
787 European Guidelines on cardiovascular disease prevention in clinical practice (version
788 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other

- 789 Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by
790 representatives of nine societies and by invited experts). *Eur Heart J*, 2012; 33:1635-1701.
- 791 58. IAS International Atherosclerosis Society. An International Atherosclerosis Society Position
792 Paper: Global Recommendations for the Management of Dyslipidemia. Available online:
793 http://www.athero.org/download/IASPPGuidelines_FullReport_20131011.pdf.
- 794 59. Ajagbe BO, Othman RA, Myrie SB. Plant Sterols, Stanols, and Sitosterolemia. *J AOAC Int*.
795 2015; 98:716-723.
- 796 60. van Ee JH. Soy constituents: modes of action in low-density lipoprotein management. *Nutr*
797 *Rev* 2009;67(4):222-34.
- 798 61. Setchell KDR. Phytoestrogens: the biochemistry, physiology, and implications for human
799 health of soy isoflavones. *Am J Clin Nutr* 1998; 68:1333S–1346S.
- 800 62. Wang H, Murphy PA. Isoflavone content in commercial soybean foods. *J Agric Food Chem*
801 1994; 42:1666–1673 .
- 802 63. Descovich GC, Ceredi C, Gaddi A, Benassi MS, Mannino G, Colombo L, Cattin L, Fontana
803 G, Senin U, Mannarino E, Caruzzo C, Bertelli E, Fragiaco C, Nosedà G, Sirtori M,
804 Sirtori CR. Multicentre study of soybean protein diet for outpatient hyper-cholesterolaemic
805 patients. *Lancet*. 1980; 2:709-12.
- 806 64. Marlett JA. Sites and mechanism for the hypocholesterolemic actions of soluble dietary fiber
807 sources. *Advances in Experimental Medicine and Biology* 1997; 427:109–21.
- 808 65. Torres N, Torre-Villalvazo I, Tovar AR. Regulation of lipid metabolism by soy protein and
809 its implication in diseases mediated by lipid disorders. *J Nutr Biochem*, 2006; 17:365-373.
- 810 66. Sirtori CR, Galli C, Anderson JW, Arnoldi A. Nutritional and nutraceutical approaches to
811 dyslipidemia and atherosclerosis prevention: Focus on dietary proteins. *Atherosclerosis*,
812 2009; 203:8-17.

- 813 67. Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy-protein
814 intake on serum lipids. *N Engl J Med* 1995;333:276–82.
- 815 68. U.S. Food and Drug Administration [Internet]. Silver Spring (MD): U.S. Food and Drug
816 Administration; 2014. Code of Federal Regulations Title 21, Volume 2, Sec. 101.82 Health
817 Claims: Soy protein and risk of coronary heart disease (CHD). 2014. [cited 2014 Oct 28].
818 Available from: <http://www.fda.gov/default.htm>.
- 819 69. Weggemans RM, Trautwein EA. Relation between soy-associated isoflavones and LDL and
820 HDL cholesterol concentrations in humans: a meta-analysis. *Eur J Clin Nutr* 2003;57:940–6.
- 821 70. Zhuo X-G, Melby MK, Watanabe S. Soy isoflavones intake lowers serum LDL cholesterol:
822 a meta-analysis of 8 randomized controlled trials in humans. *J Nutr* 2004;134:2395–400.
- 823 71. Zhan S, Ho SC. Meta-analysis of the effects of soy-protein containing isoflavones on the
824 lipid profile. *Am J Clin Nutr* 2005;81:397–408.
- 825 72. Reynolds K, Chin A, Lees KA, Knguyen A, Bujnowski D, He J. A metaanalysis of the effect
826 of soy protein supplementation on serum lipids. *Am J Cardiol* 2006;98:633–40.
- 827 73. Taku K, Umegaki K, Sato Y. Soy isoflavones lower serum total and LDL cholesterol in
828 humans: a meta-analysis of 11 randomized controlled trials. *Am J Clin Nutr* 2007;85:1148–
829 56.
- 830 74. Harland JJ, Haffner TA. Systematic review, meta-analysis and regression of randomised
831 controlled trials reporting an association between an intake of circa 25 g soya protein per
832 day and blood cholesterol. *Atherosclerosis* 2008;200:13–27.
- 833 75. Anderson JW, Bush HM. Soy protein effects on serum lipoproteins: a quality assessment
834 and meta-analysis of randomized, controlled studies. *J Am Coll Nutr*. 2011;30:79–91
- 835 76. Yang B, Chen Y, Xu T, Yu Y, Huang T, Hu X, Li D. Systematic review and meta-analysis
836 of soy products consumption in patients with type 2 diabetes mellitus. *Asia Pac J Clin Nutr*
837 2011;20(4):593-602.

- 838 77. European Food Safety Authority. Scientific Opinion on the substantiation of a health claim
839 related to isolated soy protein and reduction of blood LDL-cholesterol concentrations
840 pursuant to Article 14 of Regulation (EC) No 1924/2006. *EFSA Journal* 2012;10(2):2555.
- 841 78. Benkhedda K, Boudrault C, Sinclair SE, Marles RJ, Xiao CW, Underhill L. Health Canada's
842 proposal to accept a health claim about soy products and cholesterol lowering. *Int Food Risk*
843 *Anal J* 2014;4:1–12.
- 844 79. Sacks FM, Lichtenstein A, Van Horn L, Harris W, Kris-Etherton P, Winston M. Soy-
845 protein, isoflavones, and cardiovascular health: An American Heart Association advisory
846 panel for professionals from the Nutrition Committee. *Circulation* 2006;113:1034–44.
- 847
- 848 80. Girgih AT, Myrie SB, Aluko RE, Jones PJH. Is category A status assigned to soy-protein
849 and coronary heart disease risk reduction health claim by the United States Food and Drug
850 Administration still justifiable? *Trends Food Sci Technol* 2013;30:121–32.
- 851 81. Padhi EM, Blewett HJ, Duncan AM, et al. Whole Soy Flour Incorporated into a Muffin and
852 Consumed at 2 Doses of Soy Protein Does Not Lower LDL Cholesterol in a Randomized,
853 Double-Blind Controlled Trial of Hypercholesterolemic Adults. *The Journal of Nutrition*
854 2015;145(12):2665-2674.
- 855 82. Gouni-Berthold I, Berthold HK. Policosanol: clinical pharmacology and therapeutic
856 significance of a new lipid-lowering agent. *Am Heart J* 2002;143:356–65.
- 857 83. McCarty MF. Policosanol safely down-regulates HMG-CoA reductase—potential as a
858 component of the Esselstyn regimen. *Med Hypotheses* 2002;59:268 –79.
- 859 84. Menendez R, Amor AM, Rodeiro I, et al. Policosanol modulates HMGCoA reductase
860 activity in cultured fibroblasts. *Arch Med Res* 2001;32: 8–12.
- 861 85. NoaM, MasR, Mesa R. Acomparative study of policosanol vs lovastatin on intimal
862 thickening in rabbit cuffed carotid artery. *Pharmacol Res* 2001;43:31–7.

- 863 86. Castano G, Mas R, Fernandez L, et al. Comparison of the efficacy and tolerability of
864 policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia. *Drugs*
865 *Aging* 2003;20:153– 63.
- 866 87. Mas R, Castano G, Fernandez J, et al. Long-term effects of policosanol on older patients
867 with Type 2 diabetes. *Asia Pac J Clin Nutr* 2004;13(suppl):S101.
- 868 88. Head KA, ed. *Policosanol monograph*. Sandpoint, ID: Thorne Research Inc, 2004;9:312–7.
- 869 89. Castano G, Fernandez L, Mas R, et al. Effects of addition of policosanol to omega-3 fatty
870 acid therapy on the lipid profile of patients with type II hypercholesterolaemia. *Drugs R D*
871 2005;6:207–19.
- 872 90. Mas R, Castano G, Fernandez J, et al. Long-term effects of policosanol on obese patients
873 with Type II Hypercholesterolemia. *Asia Pac J Clin Nutr* 2004;13(suppl):S102.
- 874 91. Castano G, Menendez R, Mas R, et al. Effects of policosanol and lovastatin on lipid profile
875 and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus.
876 *Int J Clin Pharmacol Res* 2002;22:89 –99.
- 877 92. Castano G, Mas R, Fernandez JC, Fernandez L, Illnait J, Lopez E. Effects of policosanol on
878 older patients with hypertension and type II hypercholesterolaemia. *Drugs R D* 2002;3:159 –
879 72.
- 880 93. Castano G, Mas R, Fernandez L, Illnait J, Gamez R, Alvarez E. Effects of policosanol 20
881 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month
882 double-blind study. *Int J Clin Pharmacol Res* 2001;21:43–57.
- 883 94. Castano G, Mas R, Fernandez JC, Illnait J, Fernandez L, Alvarez E. Effects of policosanol in
884 older patients with type II hypercholesterolemia and high coronary risk. *J Gerontol A Biol*
885 *Sci Med Sci* 2001;56:M186–92.

- 886 95. Menendez R, Mas R, Amor AM, et al. Effects of policosanol treatment on the susceptibility
887 of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification
888 in vitro. *Br J Clin Pharmacol* 2000;50:255– 62.
- 889 96. Castano G, Mas R, Fernandez L, et al. Effects of policosanol on postmenopausal women
890 with type II hypercholesterolemia. *Gynecol Endocrinol* 2000;14:187–95.
- 891 97. Mas R, Castano G, Illnait J, et al. Effects of policosanol in patients with type II
892 hypercholesterolemia and additional coronary risk factors. *Clin Pharmacol Ther*
893 1999;65:439–47.
- 894 98. Crespo N, Illnait J, Mas R, Fernandez L, Fernandez J, Castano G. Comparative study of
895 the efficacy and tolerability of policosanol and lovastatin in patients with
896 hypercholesterolemia and noninsulin dependent diabetes mellitus. *Int J Clin Pharmacol Res*
897 1999;19:117–27.
- 898 99. Castano G, Mas R, Arruzazabala ML, et al. Effects of policosanol and pravastatin on lipid
899 profile, platelet aggregation and endothelium in older hypercholesterolemic patients. *Int J*
900 *Clin Pharmacol Res* 1999;19: 105–16.
- 901 100. Varady KA, Wang Y, Jones PJ. Role of policosanols in the prevention and treatment of
902 cardiovascular disease. *Nutr Rev* 2003;61:376–83.
- 903 101. Chen JT1, Wesley R, Shamburek RD, Pucino F, Csako G. Meta-analysis of natural
904 therapies for hyperlipidemia: plant sterols and stanols versus policosanol. *Pharmacotherapy*
905 2005;25:171-83.
- 906 102. Greyling A, De Witt C, Oosthuizen W, Jerling JC. Effects of a policosanol supplement on
907 serum lipid concentrations in hypercholesterolaemic and heterozygous familial
908 hypercholesterolaemic subjects. *Br J Nutr* 2006;95:968 –75.

- 909 103. Berthold HK, Unverdorben S, Degenhardt R, Bulitta M, Gouni-Berthold I. Effect of
910 policosanol on lipid levels among patients with hypercholesterolemia or combined
911 hyperlipidemia: a randomized controlled trial. *JAMA* 2006;295:2262–9.
- 912 104. Lin Y, Rudrum M, van der Wielen RP, et al. Wheat germ policosanol failed to lower
913 plasma cholesterol in subjects with normal to mildly elevated cholesterol concentrations.
914 *Metabolism* 2004;53:1309 –14.
- 915 105. Dulin MF, Hatcher LF, Sasser HC, Barringer TA. Policosanol is ineffective in the
916 treatment of hypercholesterolemia: a randomized controlled trial. *Am J Clin Nutr*
917 2006;84:1543-8.
- 918 106. European Food Safety Authority. Scientific Opinion on the substantiation of health claims
919 related to policosanols from sugar cane wax and maintenance of normal blood LDL-
920 cholesterol concentrations (ID 1747, 1748, 1864, 1951, 1954, 4693) and maintenance of
921 normal blood HDL-cholesterol concentrations (ID 1747, 1748, 1864, 1951, 1954, 4693)
922 pursuant to Article 13(1) of Regulation (EC) No 1924/2006. *EFSA Journal* 2011;9(6):2255.
- 923 107. Gordon RY, Becker DJ. The role of red yeast rice for the physician. *Curr Atheroscler Rep*,
924 2011; 13:73–80.
- 925 108. Burke FM. Red yeast rice for the treatment of dyslipidemia. *Curr Atheroscler Rep*, 2015
926 Apr; 17:495.
- 927 109. Ma J, Li Y, Ye Q, Li J, Hua Y, Ju D, Zhang D, Cooper R, Chang M. Constituents of red
928 yeast rice, a traditional Chinese food and medicine. *J Agric Food Chem*, 2000; 48:5220-
929 5522.
- 930 110. Mannarino MR, Ministrini S, Pirro M. Nutraceuticals for the treatment of
931 hypercholesterolemia. *Eur J Intern Med*, 2014; 25:592-599.

- 932 111. Heber D, Yip I, Ashley JM, Elashoff DA, Elashoff RM, Go VL. Cholesterol-lowering
933 effects of a proprietary Chinese red-yeast-rice dietary supplement. *Am J Clin Nutr*, 1999;
934 69:231–236.
- 935 112. Liu J, Zhang J, Shi Y, Grimsgaard S, Alraek T, Fønnebø V. Chinese red yeast rice
936 (*Monascus purpureus*) for primary hyperlipidemia: a meta-analysis of randomized
937 controlled trials. *Chin Med*, 2006; 1:4.
- 938 113. Li Y, Jiang L, Jia Z, Xin W, Yang S, Yang Q, Wang L. A meta-analysis of red yeast rice:
939 an effective and relatively safe alternative approach for dyslipidemia. *PLoS One*, 2014;
940 9:e98611.
- 941 114. Gerards MC, Terlou RJ, Yu H, Koks CH, Gerdes VE. Traditional Chinese lipid-lowering
942 agent red yeast rice results in significant LDL reduction but safety is uncertain - a systematic
943 review and meta-analysis. *Atherosclerosis*, 2015; 240:415-423.
- 944 115. Xiong X, Wang P, Li X, Zhang Y, Li S. The Effects of Red Yeast Rice Dietary
945 Supplement on Blood Pressure, Lipid Profile and C-reactive Protein in Hypertension: A
946 Systematic Review. *Crit Rev Food Sci Nutr*, 2015; [Epub ahead of print].
- 947 116. Halbert SC, French B, Gordon RY, Farrar JT, Schmitz K, Morris PB, Thompson PD,
948 Rader DJ, Becker DJ. Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin
949 (20 mg twice daily) in patients with previous statin intolerance. *Am J Cardiol*, 2010;
950 105:198-204.
- 951 117. Becker DJ, Gordon RY, Halbert SC, French B, Morris PB, Rader DJ. Red yeast rice for
952 dyslipidemia in statin-intolerant patients: a randomized trial. *Ann Intern Med*. 2009;
953 150:830–839.
- 954 118. Lu Z, Kou W, Du B, Wu Y, Zhao S, Brusco OA, Morgan JM, Capuzzi DM; Chinese
955 Coronary Secondary Prevention Study Group, Li S. Effect of Xuezhikang, an extract from

956 red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial
957 infarction. *Am J Cardiol*, 2008; 101:1689-1693.

958 119. Zhao SP, Liu L, Cheng YC, Shishehbor MH, Liu MH, Peng DQ, Li YL. Xuezhikang, an
959 extract of cholestin, protects endothelial function through antiinflammatory and lipid-
960 lowering mechanisms in patients with coronary heart disease. *Circulation*, 2004; 110:915-
961 920.

962 120. Gordon RY, Cooperman T, Obermeyer W, Becker DJ. Marked variability of monacolin
963 levels in commercial red yeast rice products. *Arch Intern Med* 2010;170:1722–1727.

964 121. Heber D, Lembertas A, Lu QY, Bowerman S, Go VL. An analysis of nine proprietary
965 Chinese red yeast rice dietary supplements: implications of variability in chemical profile
966 and contents. *J Altern Complement Med*, 2001; 7:133–139.

967 122. Imanshahidi M, Hosseinzadeh H. Pharmacological and therapeutic effects of *Berberis*
968 *vulgaris* and its active constituent, berberina. *Phytother Res*, 2008; 22:999-1012.

969 123. Pirillo A, Catapano AL. Berberine, a plant alkaloid with lipid- and glucose-lowering
970 properties: From in vitro evidence to clinical studies. *Atherosclerosis*, 2015; 243:449-461.

971 124. Lee S, Lim HJ, Park JH, Lee KS, Jang Y, Park HY. Berberine induced LDLR upregulation
972 involves JNK pathway. *Biochem Biophys Res Commun*, 2007; 362:853–857.

973 125. Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan H, Wang S,
974 Wu J, Wang Y, Li Z, Liu J, Jiang JD. Berberine is a novel cholesterol-lowering drug
975 working through a unique mechanism distinct from statins. *Nat Med*. 2004; 10:1344-1351.

976 126. Cameron J, Ranheim T, Kulseth MA, Leren TP, Berge KE. Berberine decrease PCSK9
977 expression in HepG2 cells. *Atherosclerosis*, 2008; 201:266–273.

978 127. Brusq JM, Ancellin N, Grondin P, Guillard R, Martin S, Saintillan Y, Issandou M.
979 Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for
980 the hypolipidemic effects of berberine. *J Lipid Res*, 2006; 47:1281-2188.

- 981 128. Dong H, Wang N, Zhao L, Lu F. Berberine in the treatment of type 2 diabetes mellitus: a
982 systemic review and meta-analysis. *Evid Based Complement Alternat Med*, 2012;
983 2012:591654.
- 984 129. Dong H, Zhao Y, Zhao L, Lu F. The effects of berberine on blood lipids: a systemic review
985 and meta-analysis of randomized controlled trials. *Planta Med*, 2013; 79:437-446.
- 986 130. Lan J, Zhao Y, Dong F, Yan Z, Zheng W, Fan J, Sun G. Meta-analysis of the effect and
987 safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and
988 hypertension. *J Ethnopharmacol*, 2015; 161:69-81.
- 989 131. Kong WJ, Wei J, Zuo ZY, Wang YM, Song DQ, You XF, Zhao LX, Pan HN, Jiang JD.
990 Combination of simvastatin with berberine improves the lipid-lowering efficacy.
991 *Metabolism*, 2008; 57:1029-1037.
- 992 132. Guo Y, Chen Y, Tan ZR, Klaassen CD, Zhou HH. Repeated administration of berberine
993 inhibits cytochromes P450 mRNA expression and activities in mice. *J Ethnopharmacol*,
994 2011; 138:111–118.
- 995 133. Castellanos-Jankiewicz A1, Del Bosque-Plata L, Tejero ME. Combined effect of plant
996 sterols and dietary fiber for the treatment of hypercholesterolemia. *Plant Foods Hum Nutr*,
997 2014; 69:93-100.
- 998 134. Clifton PM, Noakes M, Sullivan D, Erichsen N, Ross D, Annison G, Fassoulakis A, Cehun
999 M, Nestel P. Cholesterol-lowering effects of plant sterol esters differ in milk, yoghurt, bread
1000 and cereal. *Eur J Clin Nutr*, 2004; 58:503-509.
- 1001 135. Theuwissen E, Mensink RP. Simultaneous intake of beta-glucan and plant stanol esters
1002 affects lipid metabolism in slightly hypercholesterolemic subjects. *J Nutr*, 2007; 137:583-
1003 588.

- 1004 136. Becker DJ, French B, Morris PB, Silvent E, Gordon RY. Phytosterols, red yeast rice, and
1005 lifestyle changes instead of statins: a randomized, double-blinded, placebo-controlled trial.
1006 *Am Heart J*, 2013; 166:187-196.
- 1007 137. Cicero AF, Rovati LC, Setnikar I. Eulipidemic effects of berberine administered alone or
1008 in combination with other natural cholesterol-lowering agents. A single-blind clinical
1009 investigation. *Arzneimittelforschung*, 2007; 57:26-30.
- 1010 138. Affuso F, Ruvolo A, Micillo F, Saccà L, Fazio S. Effects of a nutraceutical combination
1011 (berberine, red yeast rice and policosanols) on lipid levels and endothelial function
1012 randomized, double-blind, placebo-controlled study. *Nutr Metab Cardiovasc Dis*, 2010;
1013 20:656-661.
- 1014 139. Pirro M, Lupattelli G, Del Giorno R, Schillaci G, Berisha S, Mannarino MR, Bagaglia F,
1015 Melis F, Mannarino E. Nutraceutical combination (red yeast rice, berberine and
1016 policosanols) improves aortic stiffness in low-moderate risk hypercholesterolemic patients.
1017 *Pharma Nutrition*, 2013; 1:73-77.
- 1018 140. Ruscica M, Gomaschi M, Mombelli G, Macchi C, Bosisio R, Pazzucconi F, Pavanello C,
1019 Calabresi L, Arnoldi A, Sirtori CR, Magni P. Nutraceutical approach to moderate
1020 cardiometabolic risk: results of a randomized, double-blind and crossover study with
1021 *Armolid Plus*. *J Clin Lipidol*, 2014; 8:61-68.
- 1022 141. Solà R, Valls RM, Puzo J, Calabuig JR, Brea A, Pedret A, Moríña D, Villar J, Millán J,
1023 Anguera A. Effects of poly-bioactive compounds on lipid profile and body weight in a
1024 moderately hypercholesterolemic population with low cardiovascular disease risk: a
1025 multicenter randomized trial. *PLoS One*, 2014; 9:e101978.
- 1026 142. Gonnelli S, Caffarelli C, Stolakis K, Cuda C, Giordano N, Nuti R. Efficacy and
1027 Tolerability of a Nutraceutical Combination (Red Yeast Rice, Policosanols, and Berberine)

1028 in Patients with Low-Moderate Risk Hypercholesterolemia: A Double-Blind, Placebo-
1029 Controlled Study. *Curr Ther Res Clin Exp*, 2014; 77:1-6.

1030 143. Pisciotta L, Bellocchio A, Bertolini S. Nutraceutical pill containing berberine versus
1031 ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in
1032 patients with familial hypercholesterolemia on stable cholesterol-lowering treatment. *Lipids*
1033 *Health Dis*, 2012; 11:123.

1034 144. Marazzi G, Pelliccia F, Campolongo G, Quattrino S, Cacciotti L, Volterrani M, Gaudio C,
1035 Rosano G. Usefulness of Nutraceuticals (Armolid Plus) Versus Ezetimibe and
1036 Combination in Statin-Intolerant Patients With Dyslipidemia With Coronary Heart Disease.
1037 *Am J Cardiol*, 2015; 116:1798-1801.

1038 145. Guardamagna O, Abello F, Baracco V, Stasiowska B, Martino F. The treatment of
1039 hypercholesterolemic children: efficacy and safety of a combination of red yeast rice extract
1040 and policosanols. *Nutr Metab Cardiovasc Dis*, 2011; 21:424-429.

1041 146. Pirro M, Mannarino MR, Bianconi V, Simental-Mendía LE, Bagaglia F, Mannarino E,
1042 Sahebkar A. The effects of a nutraceutical combination on plasma lipids and glucose: A
1043 systematic review and meta-analysis of randomized controlled trials. *Pharmacol Res*. 2016
1044 May 6;110:76-88.

1045 147. Pirro M, Mannarino MR, Ministrini S, Fallarino F, Lupattelli G, Bianconi V, Bagaglia F,
1046 Mannarino E. Effects of a nutraceutical combination on lipids, inflammation and endothelial
1047 integrity in patients with subclinical inflammation: a randomized clinical trial. *Sci Rep*. 2016
1048 Mar 23;6:23587.

1049 148. Alevizos A, Mihas C, Mariolis A. Advertising campaigns of sterol-enriched food. An often
1050 neglected cause of reduced compliance to lipid lowering drug therapy. *Cardiovasc Drugs*
1051 *Ther*, 2007; 21:133-134.

- 1052 149. Eussen SR, de Jong N, Rompelberg CJ, Garssen J, Verschuren WM, Klungel OH. Effects
1053 of the use of phytosterol/-stanol-enriched margarines on adherence to statin therapy.
1054 Pharmacoepidemiol Drug Saf, 2010; 19:1225-1232.
- 1055 150. European Food Safety Authority. A report from the data collection and exposure unit in
1056 response to a request from the European Commission. EFSA J 2008;133:1-21.
- 1057 151. Bonaccio M, Bonanni AE, Di Castelnuovo A, De Lucia F, Donati MB, de Gaetano G,
1058 Iacoviello L; Moli-sani Project Investigators. Low income is associated with poor adherence
1059 to a Mediterranean diet and a higher prevalence of obesity: cross-sectional results from the
1060 Moli-sani study. BMJ Open, 2012 ; 2(6).
- 1061 152. Katsarou A, Tyrovolas S, Psaltopoulou T, Zeimbekis A, Tsakountakis N, Bountziouka V,
1062 Gotsis E, Metallinos G, Polychronopoulos E, Lionis C, Panagiotakos D. Socio-economic
1063 status, place of residence and dietary habits among the elderly: the Mediterranean islands
1064 study. Public Health Nutr, 2010; 13:1614-1621.
- 1065 153. Associazione Medici Diabetologi (AMD) - Società Italiana di Diabetologia (SID) -
1066 Standard italiani per la cura del diabete mellito 2014.
1067
1068

*Highlights (for review)

- The cholesterol-lowering activity of some nutraceuticals (i.e. fiber, phytosterols, soy products, policosanol, red yeast rice and berberine) has been reviewed.
- The level of evidence on the cholesterol-lowering efficacy emerging from interventional studies in humans has been evaluated.
- The possible side effects associated with their use have been reported.
- The categories of patients who could benefit from their use have been established.

